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Abbreviation Full Name 
 
ABC Ammonium Bi-carbonate 
AD Alzheimer’s Disease 
AMD Automated multiple development machines 
CerS Ceramide Synthases 
CERT Ceramide transfer protein 
Cmah CMP-N-acetylneuraminic acid hydroxylase 
CNS Central nervous system 
CV Coefficient of variance 
DRM Detergent resistant membranes 
DsiaT Drosophila sialyltransferase 
ECM Extracellular matrix 
Elisa Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
ESI Electrospray ionization 
FACS Fluorescent-activated cell sorting 
GD Gaucher’s Disease 
GPMVs Giant plasma membrane vesicles 
GSL Glycosphingolipid 
HPLC High-performance liquid chromatography 
HPTLC High-performance thin layer chromatography 
LOD Limit of detection 
LOQ Limit of quantification 
LSD Lysosomal storage disease 
MS Mass spectrometer 
MS/MS Tandem MS (for molecule fragmentation) 
NeuAC N-acetylneuraminic acid 
NeuGC N-glycolylneuraminic acid 
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PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PI Phosphatidylinositol 
PNS Peripheral nervous system 
PS Phosphatidylserine 
RF Response factors 
RPLC Reverse phase liquid chromatography 
Sia Sialic acid 
SM Sphingomyelin 
SPE Solid phase extraction 
TAG Triacylglyceride 
TOF Time of flight 
Trks Tyrosine kinases 
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1. Introduction 
Cells are the fundamental units of life. These small, membrane-enclosed entities are filled with 
an aqueous solution and are brimming with staggering variety of chemicals, minerals, ions, 
proteins, nucleic acids and lipids. For a living cell it is fundamental to separate itself from its 
environment in such a way that interactions with the surroundings remain possible. This is 
achieved by encapsulating the cytoplasm with a lipid membrane. Cells depend on their 
selectively permeable membranes to import nutrients and to export by- or waste products, as 
well as for cell adhesion, cell signaling and for many other processes. Intensive research has 
provided insights into the underlying processes and allowed to extend our knowledge about 
functions of these versatile permeability barriers. Nevertheless, many aspects are still far from 
being understood. The cellular outer membrane, called plasma membrane, not only contains a 
lipid bilayer but also harbors multitude of proteins that are key to its functional capabilities 
(Daum et al., 1998). While the cell membrane research of the last decades has been mainly 
focused on proteins, lipids have been largely neglected. This is changing due to the emergence 
of new technologies (Ivanova et al., 2009; Schuhmann et al., 2012; Surma et al., 2015). But 
what is a lipid? A lipid is a small amphipathic molecule, consisting of a hydrophilic head group 
and a membrane-embedded hydrophobic moiety. Lipids have been systematized into 8 primary 
categories: fatty acyls, glycolipids, glycerophospholipids, sphingolipids, sterol lipids, prenol 
lipids, saccharolipids, and polyketides (Fahy et al., 2005).  
Of special interest for this dissertation are glycolipids that additionally contain sialic-acid and 
are then called glycosphingolipids (GSLs) or also gangliosides. Gangliosides are ubiquitously 
present on all human cells, but most abundantly in the neuronal and hepatic cells.  
1.1.  Discovery and definition of Glycosphingolipids (GSLs) 
Glycolipids consist out of one or more carbohydrate residues that are connected via glycosidic 
linkage with a hydrophobic or amphipathic lipid moiety (Fahy et al., 2005). Glycolipids 
possessing either a ceramide or sphingoid base as a lipid moiety are termed glycosphingolipids 
(Yu et al., 2011). The lipid moiety usually serves as an anchor in the plasma membrane, while 
the sugar residues are part of the extracellular matrix (ECM), with the first sugar residue partly 
embedded into the lipid bilayer of a cell (Alberts et al., 2002). Hence, they contribute to the cell- 
and species-specific profile at the cell surface. This profile undergoes constant changes, 
reflecting the stage of development, differentiation, and even oncogenic transformation, thus 
indicating the importance of these lipid molecules for cell-cell and cell-matrix interactions 
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(Cohen and Varki, 2010). In addition, glycolipids are important signal molecules for cell 
adhesion, modulation of membrane receptors and signal transduction (Eich et al., 2016). 
Gangliosides are sialic acid containing glycosphingolipids, which are in turn a subgroup of 
glycolipids. The name ganglioside was given by the German scientist Ernst Klenk in 1942, after 
he for the first time isolated lipids from ganglion brain cells and determined their chemical 
structure (Klenk, 1942).  
Close to 200 ganglioside species have been identified in vertebrates while considering only 
their different carbohydrate structures (“IUPAC-IUB Joint Commission on Biochemical 
Nomenclature (JCBN) Nomenclature of glycolipids,” 1998). If also the heterogeneity, e.g. the 
chain length and saturation of the hydrophobic lipid moiety is considered, the molecular 
structural complexity of gangliosides increases multifold.  
1.2.  Structure and biosynthesis of glycolipids 
Glycolipids are biomolecules consisting of hydrophobic or amphipathic lipid moieties linked to 
one or more carbohydrate residues through a glycosidic linkage. Hence, they contribute to both, 
the cellular lipidome and the glycome/sialome. (Cohen and Varki, 2010). Glycosphingolipids 
(GSLs) contain a great variety of carbohydrate sequences, including gangliosides and are 
classified based on their basic carbohydrate structure (see Table 1). 
Series Core Structure Abbreviation 
Arthro GlcNAcβ1,3Manβ1,4Glcβ1,1´Cer At 
Gala Galα1,4Galβ1,1´Cer Ga 
Neogala Galβ1,6Galβ1,6Galβ1,1´Cer  
Ganglio Galβ1,3GalNAcβ1,4Galβ1,4Glcβ1,1´Cer Gg 
Globo GalNAcβ1,3Galα1,4Galβ1,4Glcβ1,1´Cer Gb 
Isoglobo GalNAcβ1,3Galα1,3Galβ1,4Glcβ1,1´Cer iGb 
Lacto Galβ1,3GlcNAcβ1,3Galβ1,4Glcβ1,1´Cer Lc 
Neolacto Galβ1,4GlcNAcβ1,3Galβ1,4Glcβ1,1´Cer nLc 
Muco Galβ1,3Galβ1,4Galβ1,4Glcβ1,1´Cer Mc 
Mollu Fucα1,4GlcNAcβ1,2Manα1,3Manβ1,4Glcβ1,1´Cer Mu 
Schisto GalNAcβ1,4Glcβ1,1´Cer  
Spirometo Galβ1,4Glcβ1,3Galβ1,1´Cer  
Table 1. Carbohydrate structure of glycosphingolipids. 
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Gangliosides are synthesized in the Golgi apparatus by specific glycosyltransferases, the 
expression of which controls the steady-state levels of gangliosides at the cell surface.  
An important part of gangliosides are the sialic acids bound to their sugar moieties. Sialic acids 
(Sia) are also very interesting molecules and their distribution in nature is worth noting. An 
abundant expression of sialic acids only occurs in the deuterostome lineage (vertebrates and 
a few higher invertebrates) (Angata and Varki, 2002). In other lineages (bacteria, archaea, 
plants, fungi, protozoa and protostomes) the expression of Sia is only detected in a small 
minority of species (Vimr et al., 2004). Of these few Sia+ non-deuterostome lineage species the 
ones associated with human or animal hosts, e.g. gram-negative bacteria, are by far the 
majority and often the causative agents for serious illnesses (Varki, 2008). For example, 
neuroinvasive bacteria (Escherichia coli K1 and Neisseria meningitidis serogroup B) express 
high-molecular weight homopolymers of α2-8- and/or α2-9 lined neuraminic acid (NeuAc) 
called polysialic acid (polySia) (Vimr et al., 2004). These Sia polymers have a size and charge 
that support bacterial dissemination by downmodulation of complement activity (Allen et al., 
1987; Schneider et al., 2007). Furthermore, Neisseria meningitidis produces a serogroup B 
with such a remarkable structural similarity to the α2-8-linked polySia capsule that it impedes 
with the initiation of an immune response in human hosts (Ziak et al., 1996). Also other 
pathogenic bacteria, such as Campylobacter jejuni, have been identified to be capable to 
express remarkably complex sialoglycans on lipooligosaccharides of their outer membranes 
(Yuki, 2007). The similarity of these glycans to vertebrate brain sialoglycans can induce 
autoimmune neuropathies (Yuki and Hartung, 2012).  
Distribution of sialic acids in invertebrates is so rare, that for a long time it was perceived as 
practically non-existing, except in a few higher species (Angata and Varki, 2002). Only after 
sequencing of the Drosophila genome, it became clear that they possess similar genes required 
for the mammalian sialoglycan biosynthesis (Koles et al., 2009) and even a single 
sialyltransferase (DSiaT) (Repnikova et al., 2010). A subsequent glycan analysis of Drosophila 
glycoproteins confirmed the expression of the sialic acid N-acetylneuraminic acid (NeuAc) 
(Kraĉun et al., 1984; Aoki et al., 2007). Interestingly, expression of DSiaT gene only occurs in 
a small group of differentiated central nervous system neurons (Repnikova et al., 2010). The 
phenotype accompanying a loss of DSiaT function is characterized by a progressive loss of 
coordination and temperature-sensitive paralysis, as well as locomotor defects (Repnikova et 
al., 2010). Such symptoms could origin from possible defects in the formation and physiology 
of voltage-gated sodium channels in neuromuscular junctions. These findings point to key 
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functions of sialic acids and help to highlight the evolutionary role of sialyation in the nervous 
system. 
Interestingly, most vertebrates including human’s closest evolutionary relatives, bonobos and 
chimps, express two different sialic acids, N-glycolylneuraminic acid (NeuGc) and N-
acetylneuraminic acid (NeuAc), in significant amounts, while humans only express NeuAc 
(Chou et al., 2002). The reason for this difference in the human sialome is due to an exon 
deletion in the gene encoding for CMP-N-acetylneuraminic acid hydroxylase (CMAH) 
(Okerblom et al., 2017), which is converting N-acetyl to N-glycolyl. According to the molecular 
clock comparison, a technique used to validate the evolutionary diversion of two or more 
species based on mutation rates of DNA or amino acid sequences for proteins from fossils or 
archeological dates, the branching of the human line from the chimpanzee CMAH gene took 
place around ~3 million years ago (Chou et al., 2002). The most common hypothesis for that 
circumstance is the occurrence of a catastrophic pandemic pathogen at the beginning of the 
human lineage that targeted NeuGc. By giving rise to natural selection against a functional 
CMAH gene (Varki, 2010), this event has been termed the “sialoquake” by Varki (Varki, 2009). 
Also, the glycan mediated binding specificities of related human and non-human pathogens 
support this theory, since evolutionary changes in sialic acid binding proteins of the immune 
system postdate the loss of CMAH. But it is remarkable that the expression of NeuGc is likewise 
diminished in the brain of non-human species to the advantage of NeuAc, even though NeuGc 
is the predominant sialic acid in all other tissues. In mice for example the expression of Cmah 
gene is high in liver, thymus, spleen and kidney, but its transcripts are undetectable in the brain 
(Kwon et al., 2014). Nevertheless, the question why NeuAc is predominantly expressed over 
NeuGc in human brains is still not fully answered; possible explanations could lie in the specific 
function of NeuAc in molecular recognition processes in the brain (Davies and Varki, 2015). 
1.3.  Ceramidase expression patterns 
Besides the prior mentioned sugar moieties, the second major building block of gangliosides 
are ceramides, which play an essential role in sphingolipid metabolism in general and 
contribute significantly to membrane signaling. In mammals, ceramide is synthesized by a 
family of six ceramide synthases (CerS), each of them being responsible for specific acyl chain 
length it synthesizes (Levy and Futerman, 2010; Cingolani et al., 2016) (see Figure 1). The 
hypothesized role of ceramide as a signaling molecule made it to the center of ongoing studies 
regarding its involvement in regulating differentiation, proliferation and apoptosis of cells. 
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(Kolesnick, 2002; Pettus et al., 2002). These molecules constitute out of a sphingoid long chain 
base that is connected via an amide bond to a fatty acid. De novo synthesis of ceramide takes 
place in the endoplasmic reticulum (ER), while additional steps of sphingomyelin and 
glycosphingolipid synthesis continue in the Golgi apparatus (Futerman and Riezman, 2005). 
The transport from the ER to the Golgi apparatus proceeds either by vesicular trafficking or by 
ceramide transfer protein (CERT) across membrane contact sites between the two organelles 
(Hanada et al., 2003). De novo pathway begins with the condensation of L-serine and palmitoyl 
transferase (Hanada, 2006) generating 3-ketosphinganine, which is then reduced to 
sphinganine via 3-ketosphinganine reductase (Dolgachev et al., 2004) and followed by 
acylation of sphinganine via sphinganine N-acyl transferase to dihydroceramide. The acylation 
step of sphinganine by N-acyl transferase is a key reaction in this pathway, which is carried out 
by the prior mentioned six CerS. Futerman and Levy (Levy and Futerman, 2010) showed, that 
each member of the CerS family possesses a distinct set of features and described their 
individual tissue distribution (see Figure 2). As shown in Figure 2, CerS1 is the most dominant 
ceramide synthase in the brain, followed by CerS4 and CerS2; these enzymes - except CerS2 
- facilitate the addition of C18 or, respectively, C20 fatty acids to the C18 sphinganine (see 
Figure 1) resulting in a majority of C36 and C38 ceramides in the central nervous 
glycosphingolipids.  
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Figure 1. The ceramide synthase (CerS) family consists out of 6 enzymes, each specific for the addition 
of different acyl chain lengths. Due to this fact, ceramides can possess a variety of chain lengths and 
different degrees of saturation and α-hydroxylation. Figure was adapted from (Cingolani et al., 2016). 
 
The above findings were also supported by Ikeda et al., who analyzed the total lipid extracts of 
the mouse brain by employing the reverse phase liquid-chromatography coupled with 
electrospray-ionization fragmentation mass spectrometry (RPLC/ESI-MS/MS) and multiple 
reaction monitoring (MRM) of 25 week-old C57BL/6 mice (Ikeda et al., 2008). Results of this 
study are summarized in Figure 3 which shows that the d18:1-18:0 is the dominating ceramide 
species in mouse brain, followed by d20:1-18:0, in particular in the more complex gangliosides, 
namely GM1, GD1, GT1 and GQ1. The biosynthetic pathway of gangliosides is illustrated in 
Figure 4. Ceramide (Cer) is the starting molecule for all de novo ganglioside synthesis with the 
stepwise addition of monosaccharides to Cer. Gangliosides are divided into 4 groups:0-, a-, b-
, and c-series, depending on the number of neuraminic acid molecules connected to the 
lactosylceramide (LacCer) before the addition of GalpNAc by GM2/GD2 synthase occurs. 
Continuation of the ganglioside biosynthesis pathway after LacCer is sequentially performed 
by the enzymes β4GalNAc T1, β3Gal T4, and the sialyltransferases ST3Gal II and ST8Sia V 
(see Figure 4). 
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Figure 2. The distribution of ceramide synthases is represented in pie charts for each human organ, each 
member of the CerS family is color coded as shown in the legend. Figure was adapted from  (Levy and 
Futerman, 2010). 
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Figure 3. Ganglioside molecular species from mouse brain identified by RPLC/ESI-MS/MS and MRM 
detection. The percentage of each ganglioside molecular species has been calculated by the ratio of 
individual peak areas of individual ganglioside molecules to the total peak area. Figure was adapted from 
(Ikeda et al., 2008). 
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Figure 4. Biosynthesis pathways of gangliosides. Gangliosides are synthesized by stepwise addition of 
monosaccharides to ceramide (Cer). Gangliosides are categorized into 4 groups called 0-, a-, b-, and c-
series. The categorization depends on the amount neuraminic acid added to the lactosylceramide 
(LacCer) before the addition of GalpNAc by GM2/GD2 synthase occurs. The ganglioside biosynthesis 
pathway is continued after LacCer with the sequential work of the enzymes β4GalNAc T, β3Gal T4 (also 
called GM1a/GD1b synthase), and the sialyltransferases ST3Gal II and ST8Sia V. Figure adapted from 
(Groux-Degroote et al., 2015)  
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1.4.  Function 
1.4.1. Membrane Microdomains and Lipid Rafts 
For a long time, the working hypothesis was that cellular membranes consist out of a 
homogenous liquid or fluid phase formed by the lipid bilayer (Singer and Nicolson, 1972). It 
was first in the 1970s when it became clear that lipids and proteins can move laterally in the 
lipid bilayer, i.e. that cell membranes are fluids. Gradually accumulating evidence suggested, 
that plasma membranes can sub-compartmentalize. This is based on the weak affinity between 
sphingolipids and cholesterol, which organize dynamic assemblies that can form functional 
platforms in the membrane. Such compartmentalization principle is based on 2-dimensional 
phase separation. Simple model systems consisting out of sphingomyelin, unsaturated 
phospholipids and cholesterol can form two liquid phases, the liquid-disordered (Ld) and liquid-
ordered phase (Lo) (Simons and Ikonen, 1997). The Ld-phase is characterized by high lateral 
mobility and consists of disordered acyl chains with conformational low order in the unsaturated 
phospholipids (Hancock, 2006). The (Lo)-phase on the other hand is more ordered (liquid-
ordered) and the hydrophobic moieties are saturated. This segregation depends on cholesterol 
due to its rigid sterol ring favoring interactions with straighter, stiffer hydrocarbon chains of 
saturated lipids and hence, disfavors interaction with the more flexible unsaturated lipid 
species, resulting in lateral segregation (Lingwood and Simons, 2010). Thus, cholesterol 
induces a liquid-liquid phase separation into a unique Lo phase and the Ld phase. Plasma 
membranes can also phase separate into liquid-ordered and –disordered phases. Especially 
glycosphingolipids form ordered domains in the phospholipid bilayer, due to the affinity of 
sphingolipids to form hydrogen bonds and their affinity to cholesterol (Abrahamsson et al., 
1977; Thompson and Tillack, 1985). This has been shown microscopically in giant plasma 
membrane vesicles (GPMVs) (Sezgin et al., 2012). The fact that biological membranes are not 
as homogenous as previously thought was also observed by the aggregation of sphingolipids 
(Thompson and Tillack, 1985) and resulted in the suggestion that sphingolipid microdomains 
may be the reason for differences in the lipid composition of the apical and basolateral plasma 
membrane of epithelial cells (Simons and van Meer, 1988). Simons and van Meer suggested, 
that sphingolipid microdomains can influence the apical lipid sorting process in the trans-Golgi 
network and this hypothesis has been supported when an apically sorted protein was shown 
to be associated with sphingolipids, enriched in detergent-resistant membranes (DRMs) 
insoluble to the detergent Triton X-100 at 4°C (Brown and Rose, 1992). All these studies 
prompted Simons and Ikonen to postulate their lipid raft concept, in which they propose the 
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existence of sphingolipid- and cholesterol enriched membrane microdomains with a higher fatty 
acid chain order that contribute to various cellular processes, such as assembly of signal 
platforms and the formation of vesicular carriers in membrane trafficking (Simons and Ikonen, 
1997). These lipid rafts are defined as small lipid or membrane rafts (10-200 nm), 
heterogenous, highly dynamic, sterol- and sphingolipid-enriched membrane domains that 
compartmentalize cellular processes (Simons and Ikonen, 1997). In the resting state, the raft 
lipids and proteins form fluctuating nano-assemblies which can be clustered to form larger and 
more stable platforms that are key to their biological function. Using stimulated emission 
depletion (STED) microscopy it was possible to show the existence of small membrane areas 
(< 20 nm), where glycosylphosphatidylinositol (GPI)-anchored proteins where enclosed by lipid 
rafts lipids, i.o. sphingomyelin (SM), GM1 and cholesterol, for an average lifespan of 10-20 ms 
and thus, forming transient and dynamic molecular complexes (Eggeling et al., 2009a, 2009b). 
Because glycosphingolipids and gangliosides can form such dynamic structures, the lipid raft 
principle will be an important element in elucidating ganglioside function. So far most of this 
work remains to be done. The capability to form functional larger platforms (Pike, 2006) in a 
sterol-dependent manner (Sharma et al., 2004; Eggeling et al., 2009b) may be essential for the 
biological role that gangliosides play, for instance in cell-cell interactions (Baumgart et al., 2007; 
Lingwood et al., 2008). 
1.4.2. Microdomains in the brain 
The compartmentalization of cellular membranes and existence of membrane microdomains is 
probably more evident in the brain than in any other tissue. Cells of the central nervous system 
(CNS), but also in the peripheral nervous system (PNS), are highly specialized, which is also 
reflected in their morphology (Zhang and Cui, 2014, p. 2). Neurons, oligodendrocytes, Schwann 
cells (in the PNS) and to a lesser extent astrocytes are highly polar cells, hence 
compartmentalization of signaling events is required in order to maintain normal neuronal 
physiology, including neuronal differentiation, polarization, synapse formation, synaptic 
transmission and glial-neural interactions (Marin et al., 2013). This is achieved by the 
polarization of the neuronal plasma membrane into somatodendritic, axonal and synaptic 
membrane macrodomains, while myelinating cells have a multi-layered myelin-sheath and 
nodal domains (Poliak and Peles, 2003). Although neuronal membrane regions lack 
morphologically distinguishable cell junctions such as tight junctions in epithelial cells, lateral 
diffusion is hindered between the plasma membrane domains, isolating these membrane 
compartments from each other (Jacobson et al., 1995). The role of lipid rafts in the brain has 
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been analyzed over the years and particular lipids, and specific subsets of membrane proteins 
have been identified to be necessary for the function of neuronal lipid membrane domains (see 
Table 1 in review (Sonnino et al., 2014)). These reports were also supported by a growing 
number of proteomics studies (Cayrol et al., 2011; Hashimoto et al., 2012; Shah et al., 2015). 
Membrane receptors are most prominent proteins in neuronal cells, whose function often 
depends on integration into specific lipid membrane domains. Among these receptors tyrosine 
kinases (Trks) are probably the most important ones, since they are crucial in the mediation of 
cell-cell interactions.  
During the maturation processes in the brain, i.e. after birth and during the aging processes, 
the lipid homeostasis in the nervous system is changing and various neurodegenerative 
diseases cause alterations in the homeostasis, ultimately affecting the organization of lipid 
rafts. Understanding these processes better can facilitate the development of improved 
therapies for neurodegenerative disease treatment. This topic is addressed in section 1.6.  
1.5.  Localization and quantities of gangliosides in the mammalian brain 
The expression, sorting and turnover of constituents of the membrane is a tightly regulated 
process which continues along with the development of cells and tissues. Each cell type has 
its own individuality. Of all the different cell membrane lipids, the highest structural complexity 
is seen for glycosphingolipids (GSLs), as already described before in section 1.2 Structure and 
biosynthesis of glycolipids The expression of a developmentally regulated cell-specific lipid 
pattern, for example the GSLs in the nervous tissue, requires a complex set of biosynthetic and 
catabolic enzymes (Yu et al., 2009; Aureli et al., 2011) and an extremely complex trafficking 
and sorting machinery (van Meer and Hoetzl, 2010; Tidhar and Futerman, 2013; Sonnino et 
al., 2014). Glycolipids are present on probably all eukaryotic cells and account overall for 5% 
of all lipid molecules in the outer monolayer of the plasma membrane bilayer (Kraĉun et al., 
1984). Internal cell membranes also contain glycolipids, but mostly in the post-Golgi organelles 
(Möbius et al., 1999). Sialic acid containing glycolipids, the gangliosides, are in general only 
marginally expressed in most eukaryotic cells and only nerve cells show a significant 
expression accounting for 5-10% of the total lipid mass (Schnaar et al., 2014). Gangliosides 
occur primarily on the plasma membrane, with the ceramide compartment anchored in the 
membrane together with most of the first sugar moiety  (commonly glucose,see Figure 4) 
engaged with the lipid leaflet, while the remaining glycan part reaches into the ECM (DeMarco 
and Woods, 2009). The quantity as well as the complexity of gangliosides are subject to a 
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continuous change in living organisms. These changes vary for different organs and are also 
age dependent. Clues about the function of glycolipids can be drawn from their localization. For 
example, glycolipids are confined to the apical surface of the plasma membrane of epithelial 
cells, where they are involved in protecting the membrane against extracellular noxious 
conditions, for instance low pH-values and high concentrations of degrading enzymes in the 
stomach (Sato et al., 2005, p. 200). The sialic acid that gangliosides are carrying adds a net 
negative charge to them. This electrical effect is of importance, since the presence of 
gangliosides changes the electrical field across the membrane and thus the concentration of 
ions, especially Ca2+, at the membrane surface (Schnaar et al., 2014). It is also well established 
that glycolipids function in cell-recognition processes, were the sugar groups on glycolipids and 
glycoproteins serve as binding partners for membrane-bound carbohydrate-binding proteins, 
called lectins, during cell-adhesion. Mice with induced gene deficiencies for the biosynthesis of 
complex gangliosides, i.o. GD1a, GD1b, GT1b, GQ1b, showed abnormalities in the central 
nervous system, including axonal degeneration and reduced myelination (Norton and Poduslo, 
1973). 
In all mammals the composition of glycoconjugates, including glycolipids, glycoproteins, and 
proteoglycans are constantly changing during neural development (Yu et al., 1988; Ngamukote 
et al., 2007; Yanagisawa and Yu, 2007). Changes in the expression of glycolipids, in particular 
gangliosides, correlate with neurodevelopmental events (Yu et al., 2009; Xu et al., 2010; Yu 
and Itokazu, 2014; Itokazu et al., 2017). For instance, in mice the fertilized egg itself strongly 
expresses the globo-series of glycolipids (see Table 1), e.g., the stage-specific embryonic 
antigen, SSEA-3/SSEA-4. As the fertilized egg continues to proliferate, the lacto-series 
becomes predominantly expressed around embryonic day (E)1.5, which is later followed by the 
ganglio-series GSLs in the developing brain of the embryo at E7 (Xu et al., 2010). As mentioned 
before, the lipid moiety of gangliosides, ceramide, is in turn synthesized from a sphingosine 
base and a fatty acid residue in the endoplasmic reticulum (ER). From there, ceramide is 
transferred to the Golgi apparatus and glycosylated to glucosylceramide (GlcCer) (see Figure 
4) at the cytosolic leaflet of the cis-Golgi, which is abundant in early embryonic mouse brain 
from E16 (Ngamukote et al., 2007). In the next step, GlcCer is transported to the trans-Golgi 
by the phosphoinositol 4-phosphate adaptor protein 2 (FAPP2) and trans-located to the luminal 
side of the Golgi vesicle (D’Angelo et al., 2007, 2013). FAPP2 is also a mediator for GlcCer 
transportation from the cis-Golgi back to the ER (Halter et al., 2007). There, GlcCer gets flip-
flopped back into the lumen of the ER and is then shuttled by the vesicular transport towards 
the lumen of the Golgi (Chalat et al., 2012). This is the location where GlcCer gets converted 
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to lactosylceramide (LacCer) (see Figure 4). At this stage the carbohydrate moieties of the 
gangliosides can be elongated via catalyzation by sialyltransferases (GM3 of the a-series) and 
galactosyltransferase (GA2 of the asialo-series). The biosynthesis proceeds as shown in Figure 
4.  
GM3 and GD3 are expressed in large quantities in early embryonic rodent brains, as more 
simple gangliosides are commonly expressed at the beginning of brain development. Upon 
later developmental stages the ratio shifts more towards the already mentioned complex 
gangliosides, GM1, GD1a, GD1b, and GT1b, that will also remain throughout the adult life the 
dominant brain gangliosides (Yu et al., 1988; Ngamukote et al., 2007). However, the ratio 
between them will continue to shift with progressing age (O’Brien and Sampson, 1965; Norton 
and Poduslo, 1973; Sastry, 1985).  
On one side the constant change of ganglioside expression with progressing brain 
development and age, on the other the different technical and analytical approaches that have 
been used to quantify brain gangliosides, make it difficult to state robust numbers for their 
quantity. For example, in several studies the gangliosides present in the brain of Alzheimer’s 
disease were investigated, but the reported results are not consistent, because in each study 
the peak area taken from the chromatogram to calculate the concentration was selected 
manually and hence, not reproducibly (Crino et al., 1989; Kracun et al., 1990, 1991; 
Svennerholm, 1994). 
Nevertheless, overall basic trends could and have been identified; as mentioned before, 
gangliosides can make up to 5-10% of the total lipid mass in nervous cells (Wang and Brand-
Miller, 2003). In the brain, grey matter and neurons are highly enriched with gangliosides, while 
the sphingolipid species sphingomyelin (SM), galactosylceramide (GalCer) and sulfatide are 
enriched in oligodendrocytes and myelin (O’Brien and Sampson, 1965; Aureli et al., 2015). The 
brain grey matter contains four to five-fold more ganglioside content per mg of protein than the 
brain white matter (Kracun et al., 2002). The development of a method that more precisely 
quantifies the major ganglioside classes within the mammalian brains will boost the 
understanding of the role and function of this lipid class in health as well as in disease. 
1.6.  Diseases 
The expanding knowledge about cellular lipidomes gives rise to new ideas and hypotheses, 
which are brought forward and illuminate how the membrane composition of different cells 
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impacts the function as well as dysfunction of cells and whole organs, eventually resulting in 
disease. Most prominent, with regard to gangliosides, are the glycosphingolipidoses (Sandhoff 
and Kolter, 2003), a prototypical family of lysosomal storage diseases (LSDs). LSDs are 
characterized by defects in the catabolism of GSLs and share some features with other 
lysosomal disorders (Vitner et al., 2010). These disorders only occur at a low rate of 1 in 5,000 
live birth in humans and lead to a severe monogenic disease, typically inherited as autosomal 
recessive traits (Platt, 2014). For a long time, it was presumed that diseases related to GSL 
biosynthesis are nonexistent due to the in utero lethality. Indeed, experiments in mice showed 
that a loss of function mutation for the very first enzyme GlcCer synthase (See Figure 4) 
catalyzing the GSL biosynthesis leads to embryonic lethality due to the inability of the embryo 
to develop past gastrulation (Yamashita et al., 1999). However, loss of function in genes 
encoding for enzymes more downstream of the GSL biosynthesis are viable (Proia, 2003). By 
achieving double knockouts for the enzymes GalNAcT and GD3S, the biosynthesis for all a- 
and b-series gangliosides (see Figure 4) could be inhibited in mice (Kawai et al., 2001; Inoue 
et al., 2002). While it was possible to obtain viable mice with these knockouts, severe 
phenotypes could be observed such as spontaneous adult lethality. Shortly after weaning was 
stopped the double mutant mice began to die. At 13 weeks of age more than 50% of the mice 
had died of unknown cause, with the mortality rising to 92% at 36 weeks of age (Kawai et al., 
2001). Interestingly, the cause of death seems to differ between the two independent studies. 
The mice from Kawai et al. 2001 seemed to be very sensitive to sound-induced seizures; nearly 
100% of the animals could be induced to have a lethal seizure by just jangling a standard set 
of house keys (Kawai et al., 2001), however the mice of Inoue et al. 2002 did not have such a 
susceptibility to sound induces seizures (Inoue et al., 2002). Inoue et al. suggested possible 
modifier background loci as a reason for this different phenotype, yet his mouse line showed 
propensity for skin injury. A likely reason for such a phenotype could be a peripheral nerve 
degeneration leading to reduced sensory function and inadvertent injury to the skin (Proia, 
2003). 
Altogether, it could be shown that the complex ganglioside structures (a- and b-series 
gangliosides) are not necessary for the development of the mammal nervous system. 
Nonetheless, due to the essential role of complex gangliosides in myelin stability and axonal 
glia signaling they are a necessity for a functioning nervous system after birth. 
There is only a small number of genetically confirmed disorders in humans for ganglioside 
biosynthesis, namely the deficiency of GM3-synthase (Simpson et al., 2004) and GM2-
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synthase (Boukhris et al., 2013; Harlalka et al., 2013) (see Figure 4). While the GM3-synthase 
deficiency resulted in a severe epilepsy syndrome, the clinical picture for the GM2-synthase 
deficiency resulted in a spastic paraplegia, characterized by lower limb weakness and 
spasticity. Measurements of blood plasma levels of GSLs in the patients verified the predicted 
deficiencies in GM2 or GM3, respectively and their downstream derivatives. The precursors of 
GM2 or GM3 were elevated due to the block in the biosynthesis pathway of gangliosides 
(Simpson et al., 2004; Harlalka et al., 2013). Remarkable was the discovery of minor amounts 
of a previously unknown GSL structure called sialylated Gb3 in GM2-synthase deficient 
patients (Harlalka et al., 2013). Whether the disease is caused by the loss of a specific 
ganglioside species, by the elevation of the precursor molecules or by an imbalance in the 
charge/neutral GSL ratios, is yet to be determined (Proia, 2004). While these are the first two 
disorders within human populations known to originate from the inability to synthesize complex 
gangliosides, it is possible that in the future more deficiencies will be identified regarding other 
enzymes that are part of the ganglioside biosynthesis pathways (see Figure 4). 
Whereas disorders in GSL anabolism are rare, this is not true for GSL catabolism defects 
(Schultz et al., 2011). The latter form an important subgroup of a larger family of more than  
70 LSDs. The clinical picture of many LSDs is of progressive neurodegenerative nature, that 
often starts already in infancy or during the childhood (Platt and Walkley, 2004). With that being 
said, symptoms and progression of LSDs have also been reported to start at any other stage 
of life, but with a lower probability (Sedel, 2007; van der Beek et al., 2012). The understanding 
of the working mechanisms of LSDs was propelled forward considerably, when more and more 
animal models became available for these disorders; ranging from genetically engineered mice 
(Platt and Lachmann, 2009) to spontaneous mutants found in species such as cats, dogs, 
sheep, cattle (Hemsley and Hopwood, 2010) and even a flamingo with Tay-Sachs disease 
(Zeng et al., 2008). These spontaneous mutations include GM1-gangliosidosis (Sandhoff and 
Harzer, 2013), caused by defects in the lysosomal degradation of gangliosides, certain forms 
of Gaucher’s disease (GD) (Vitner and Futerman, 2013), caused by defects in lysosomal 
glucosylceramides activity, as well as Niemann-Pick disease type A (Ledesma et al., 2011) that 
originates from a lack of acidic sphingomyelinase. The common factor of these pathologies is 
accumulation of undegraded sphingolipids, because of the enzymatic defects. Examples are 
different gangliosides in gangliosidosis, glucosylceramide in the case of GD, and 
sphingomyelin in the case of Niemann-Pick disease type A. It appears, however, that trafficking 
from the lysosomal membranes with abnormal SL composition to the plasma membrane 
(Reddy et al., 2001) causes notable changes in the plasma membrane lipid composition 
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(Scandroglio et al., 2008; Buccinnà et al., 2009; Ledesma et al., 2011). The study of the 
progression of these disorders with such a variety of accumulating lipid species, has led to the 
increased understanding of these disorders, culminating in the development of therapies for 
different LSDs (Brady et al., 2001; Ioannou et al., 2001; Zervas et al., 2001; Patterson et al., 
2007). This success stands in contrast to the much more wide spread sporadic 
neurodegenerative diseases, such as Alzheimer’s disease, where the shortage of authentic 
animal models contributes to a lack of potential treatment options available (Laurijssens et al., 
2013). 
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by loss 
of neurons in the cerebral cortex and subcortical regions, atrophy and degeneration in the 
temporal lobe and parietal lobe as well as in parts of the frontal cortex and cingulate gyrus 
(Ariga et al., 2008). The cause of the development of AD is still not completely understood, but 
the deposition of amyloid β-protein (Aβ), which is a cleaved product of its precursor protein, 
amyloid precursor protein, APP, in the brains of patients affected with AD is clear. A better 
understanding of the assembly of soluble Aβ unto amyloid fibrils would not only promote our 
knowledge of AD but also of other human amyloidosis, such as prion disease and pancreatic 
islet amyloidosis, in which non-toxic proteins are assembled into their pathological, toxic forms. 
Yanagisawa et al. discovered already in 1995 a unique ganglioside-bound form of Aβ (GAβ) in 
membrane fraction prepared from brains that exhibited early pathological changes of AD 
(Yanagisawa et al., 1995). In fact, GAβ was characterized by its binding to GM1 and based on 
this molecular characterization it was hypothesized that GM1-bound Aβ acts as a seed for Aβ 
assembly in the AD brain, because it shows a strong tendency to form large Aβ assemblies 
and has altered immunoreactivity (Yanagisawa et al., 1997). This hypothesis was later 
confirmed by several in vitro studies (McLaurin et al., 1998; Matsuzaki and Horikiri, 1999; Ariga 
et al., 2001; Kakio et al., 2001), particularly Matsuzaki et al. reported that binding of Aβ to GM1 
is facilitated in cholesterol-rich environment, and it is dependent on cholesterol-induced GM1 
clustering in rafts in the host membranes (Matsuzaki and Horikiri, 1999; Kakio et al., 2001). 
Strikingly, there are several familial inheritable types of AD caused by several mutations within 
the Aβ sequence that induces Aβ assembly and deposition, which preferentially occur in 
specific but different areas in the brain, where Aβ interacts with specific gangliosides. The 
Dutch-, Italian- and Iowa-type mutations induce Aβ depositions particularly in cerebral blood 
vessel walls, while the Arctic-type mutation induces predominant Aβ deposition in the 
parenchyma of the cerebral cortex and are all mutations of APP (Tsubuki et al., 2003). Finally, 
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there is also a Flemish-type mutation that induces Aβ deposition starting from the outer surface 
of cerebral blood vessels (Tsubuki et al., 2003).  
Aβ protein can also be enzymatically cleaved into two peptides, Aβ40 and Aβ42. It has been 
suggested that, due to their different effects on cell function, the Aβ40 and Aβ42 peptides 
initially disrupt the membrane lipid environment, thus impairing the activity of various proteins 
involved in signal transduction and ion fluxes (Roth et al., 1995). Aβ peptides may alter the 
neuronal membrane lipid environment by inducing lipid peroxidation and/or changing lipid 
fluidity. It has also been shown that Aβ40 increased both annular and bulk fluidity of synaptic 
plasma membranes (Avdulov et al., 1997). On the other hand, in lymphocyte membranes as 
well as in membranes isolated from cortex, hippocampus, striatum, and cerebellum, it was 
shown that Aβ40 decreases the bulk fluidity (Müller et al., 1995). Most likely, the different 
cellular lipid composition is the reason for this disparity. Also, both Aβ peptides seem to have 
different binding preferences regarding gangliosides. Aβ40 as well as Aβ42 were reported to 
form a stable and specific complex with GM1, but to a lesser extent  with more complex 
gangliosides such as GD1b and GT1a (McLaurin et al., 1998; Evangelisti et al., 2013). The 
interaction of Aβ with gangliosides in the neuronal membrane may be only one of several 
mechanisms by which the membrane fluidity and/or membrane integrity could be disrupted by 
Aβ and a possible explanation for the increased permeability to ions and dysregulation of signal 
transduction systems seen in the presence of Aβ (Roth et al., 1995). 
Besides of their role in neuronal disorder, gangliosides, especially GD2, have recently gained 
a lot of attention in cancer research. Gangliosides GM2, GD2 and GD3 are highly expressed 
in human tumors of neuro-ectodermal origin, such as melanomas, gliomas, and 
neuroblastomas, but in contrast, they are mostly absent or very low expressed in healthy 
tissues (Lloyd and Old, 1989; Hakomori, 1996). The exception is GD2, which is also highly 
expressed on bone marrow-derived mesenchymal stem/stromal cells (MSCs) and serves as a 
marker for them during prospective isolation (Martinez et al., 2007). Intriguingly, over the last 
years GD2 was established as a marker and a possible therapeutical target among pediatric 
and adult solid tumors, including neuroblastoma, glioma, retinoblastoma, Ewing's family of 
tumors, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, 
small cell lung cancer, melanoma and breast cancer (Mennel et al., 1992; Martinez et al., 2007; 
Jin et al., 2010; Yanagisawa et al., 2011; Battula et al., 2012; Kailayangiri et al., 2012; Liang et 
al., 2013; Ahmed and Cheung, 2014). What makes GD2 especially appealing for targeted 
immunotherapy is its high concentration in tumor cells and restricted expression in healthy 
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tissue (Wu et al., 1986; Cheung et al., 1987; Tsuchida et al., 1989; Chang et al., 1992; Lammie 
et al., 1993; Modak et al., 2002). The National Cancer Institute pilot program for the prioritization 
of cancer antigens ranked GD2 as the 12th most important cancer antigen out of 75 potential 
targets, thus highlighting its potential in cancer therapies (Cheever et al., 2009).  
It was demonstrated that GD2  can be a marker for breast cancer stem cell (Battula et al., 
2012). GD2+ cells identify a small fraction of cells in human breast cancer cell lines that not 
only show similar gene expression patterns as CD44hiCD24lo, but can also form 
mammospheres in cell culture and induce tumors in NOD/SCID mice upon injection of as few 
as 10 GD2+ cells (Battula et al., 2012). What function GD2 fulfills in cancer stem cells is yet not 
understood, but it is recognized that gangliosides for instance facilitate cell-cell communication 
between immune cells and that gangliosides are widely expressed on tumor cells (Hakomori, 
1996, 2001). Thus, a hypothesis has been proposed that gangliosides help tumor cells escape 
immune clearance within the tumor microenvironment (Potapenko et al., 2007). This seems to 
be the case not only for GD2, but also for GD1a, GD1b, GD3, and GM3 (Ravindranath et al., 
2005; Potapenko et al., 2007; Mukherjee et al., 2008). Additionally, it has been reported that 
gangliosides can induce apoptosis in immune cells important for fighting tumor cells, such as 
T- and NK cells (Biswas et al., 2006; Sa et al., 2009). 
In summary, gangliosides are involved in many cellular processes and their dysregulation 
seems to be involved in a variety of severe disorders, ranging from lipid storage diseases over 
neurodegenerative diseases to cancer and possibly other diseases involving either a lack or 
overreaction of the immune system.  
1.7.  Analytical methods for lipidomics 
Key to progress in the lipidomic field has been the development of diverse analytical methods, 
which have progressed over time owing to technological improvement. Most importantly were 
the advances in mass spectrometers, resulting in increased sensitivity, higher mass accuracy, 
higher scan speeds, and the ability to acquire in both positive and negative mode in one run. 
Overall that lead to an increased popularity of MS as a detection technique for biomolecules in 
recent years (Ivanova et al., 2009; Surma et al., 2015; Zhang et al., 2015). In this chapter an 
overview regarding the most important techniques will be given. Independently of the 
subsequently used analysis method, the first and one of the most important steps is lipid 
extraction. This probably trivial sounding procedure is actually a very important point due to the 
different characteristics of lipids, many of which are non-polar and hydrophobic, while some 
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polar and hydrophilic. Furthermore, lipids are frequently associated with other biological 
compounds in the sample and cannot be extracted so easily. An overview of the most common 
methods used is provided in the following. 
1.7.1. Lipid extractions 
A multitude of lipid extraction methods exist, reflecting the diverse nature of individual lipid 
classes and membrane complexity, as well as the source material (e.g. liquid or solid). 
Generally, the different methods can be distinguished by several main categories. Most 
widespread is the use of organic solvents (Folch et al., 1957; Bligh and Dyer, 1959; 
Svennerholm and Fredman, 1980; Ladisch and Gillard, 1985), such as chloroform-methanol-
water mixtures, or silica extractions (Neoh et al., 1986) which are also common extractions 
methods. Nowadays, in lipidomic studies most widely employed are mixtures of organic 
solvents, in particular, a chloroform-methanol mixture based on Bligh and Dyer from 1959, that 
uses an additional water phase to extract the lipids from biological materials (Bligh and Dyer, 
1959). Despite the age of this method, most variations are only concerning the reduction of 
organic solvents employed in it. For the extraction of gangliosides, a protocol developed by 
Svennerholm and Fredman (Svennerholm and Fredman, 1980) combined with a method 
developed by Ladisch and Gillard (Ladisch and Gillard, 1985) are frequently used. 
The most suitable extraction method needs to be chosen considering the physicochemical 
features of the lipids of interest, e.g. amphiphilicity or chemical structure, and which parts of the 
membranes are supposed to be investigated. For biological samples, e.g. tissues, cells and 
body fluids, an optimization or modification of existing techniques is often necessary. Two of 
the major challenges to overcome are the extraction efficiency and a complete removal of the 
nonlipid content. Additionally, the sample throughput and reproducibility are important factors 
that need to be optimized. Polar lipids that contain hydrophilic as well as hydrophobic groups 
are commonly extracted with a mixture of chloroform and methanol (Pati et al., 2016). For non-
polar lipids, that lack hydrophilic groups, alkane solvents are better suited for the extraction 
(Efthymiopoulos et al., 2018). The non-polar lipids include triglycerides, diglycerides, 
monoglycerides and sterols, while polar compounds are phospholipids, free fatty acids and 
sphingolipids.  
Lipids can bind to proteins and carbohydrates, resulting in the formation of glycolipids and 
lipoproteins. Such formations influence the solubility of the lipids and may alter the 
requirements for suitable solvents to extract them. Depending on the nature of the lipids of 
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interest, a variety of solvent mixtures and methods can be utilized to solubilize these lipid 
classes. The improved understanding of lipidomics has paved the way for the distinction 
between “total lipid extracts” and “extractable lipids” (Jahnke et al., 2015). 
For the purpose of this project, the most important method to start with was a modified 
Svennerholm (Svennerholm and Fredman, 1980) and Ladisch (Ladisch and Gillard, 1985) 
method for ganglioside extraction. 
1.7.2. Thin layer chromatography (TLC) 
Thin layer chromatography (TLC) is the classic way to analyze lipids and it set the field moving 
decades ago. Even William Christie, one of the most well-known experts for lipid analysis, 
asked himself already in 1990 if “TLC had its day?” (Christie, 1990). About 30 years later, TLC 
is still around and one of the most important methods to analyze lipid samples and their content. 
The reasons for the longevity of TLC are many, but one of the most important ones were the 
increasing commercial availability of pre-coated TLC plates that improved the possible inter-
site reproducibility, since it could be implemented in different laboratories without compromising 
reproducibility anymore compared to the home-made TLC plates which were used before. This 
development was also accompanied by a vast increase in the possible absorbent materials 
with which the plates can be coated; most prominently, high-performing silica, bonded phases 
and impregnated layers have helped to boost the versatility of high-performance TLC (HPTLC) 
and made them an indispensable tool of modern analytical chemistry (Peterson and 
Cummings, 2006). The main difference between TLC and HPTLC lays in the different particle 
sizes of the stationary phases and the care that is used to apply the samples and to process 
obtained data (“The Evolution of Thin-Layer Chromatography,” 2008). Despite its limitations 
and concerns for the wider use of TLC, e.g. due to the lower chromatographic resolution in 
comparison to high-performance liquid chromatography (HPLC) as well as the potential 
oxidation of the analyte caused by its exposure to atmospheric oxygen, the benefits of HPTLC 
make it still a useful and competitive method compared to other modern methods (Fuchs et al., 
2008). 
To name just a few of the advantages of HPTLC; the application of commercially available 
ready-made TLC plates allows even the less experienced users perform good separations and, 
additionally, makes the technique convenient and simple. Compared to other techniques, such 
as HPLC-MS, the needed equipment for HPTLC is inexpensive and therefore can be afforded 
by more labs, without the need to specialize to a high degree to perform experiments. On the 
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same note, also the solvents used for a HPLC-MS set up are of much higher quality than for 
HPTLC, which increases the running costs. While HPLC columns can have a “memory” effect 
for previous analytes, TLC uses always a fresh stationary phase and hence does not face the 
problem of contaminated molecules from previous runs. It is also possible to apply several 
samples simultaneously on a HPTLC, while a HPLC can only process one sample at a time. 
In lipid analysis TLC is still a benchmark and classically used for routine separations, 
identification of lipids and their rough quantification in the sample. A lasting limitation of stand-
alone TLC is and will be the non-existing ability to provide information on the molecular lipid 
composition of a sample and not only a guess about the quantities of the class levels. But with 
the technological progress in this field, automated multiple development (AMD) machines have 
become available, enabling a more productive and less labor-intensive way to mix the solvents 
and perform the development and drying process (Zellmer and Lasch, 1997). 
1.7.3. Immunoassays 
Immunoassays encompass any use of an antibody-based method to detect a specific protein 
or lipid in a sample. Usually they are not stand-alone, meaning they are coupled with another 
analysis method, e.g. fluorescence-activated cell sorting (FACS) in flow cytometry, enzyme-
linked immunosorbent assay (ELISA) and immunohistochemistry, to name some of the most 
prominent representatives of this category. The common denominator for all assays is antibody 
binding. Undoubtedly, one of the biggest strength of immunoassays is their analytical sensitivity 
and their overall robustness, but there is a string of problems that can be associated with 
immunoassays, leading to occasional analytical errors. One is the possible lack of adequate 
specificity and accuracy. Many factors can influence the ability of an antibody to find and bind 
its epitope, compounds or patient conditions can interfere with clinical immunoassay 
measurements. Generally, these factors are divided in two categories:(1) exogenous errors, 
arising from wrong sample preparation, and (2) endogenous interferences, when endogenous 
antibodies bind to, bridge, or block the binding sites of the signal antibodies, leading to false 
negative or false positive results of the assay.  
Endogenous interferences can be very difficult to be spotted. Exogenous errors, on the other 
hand, can occur randomly, e.g. due to variability in sample pipetting, or systemically, e.g. due 
to calibration errors. They can be prevented by good internal quality control (Zarbo et al., 2002) 
and sporadic external quality assessments (Sturgeon and Viljoen, 2011). A useful parameter 
to assess the robustness of immunoassays can be to study the outlier rate (Ungerer et al., 
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2010). But there can also be many more basic problems existing, which are easier to spot, 
such as degradation of the molecule of interest bearing the target epitope by wrong sample 
handling.  
The biggest limitation of immunoassays for ganglioside determination is the lack of high-quality 
antibodies. It is still very difficult to produce specific antibodies against lipids including 
glycosphingolipids. Therefore, these assays have limited use in this field. 
1.7.4. Mass Spectrometry (MS) Technologies 
Due to the advancement in computational technologies, mass spectrometry has evolved over 
the last decade rapidly and enabled MS methods to revolutionize lipid science, helping 
lipidomics to emerge as one of the most promising research fields (Yang and Han, 2016). The 
two major MS methods are the high-performance liquid chromatography (HPLC) coupled with 
mass spectrometry (MS), which is the most widespread method to analyze lipidomes and 
glycosphingolipids, and the shotgun-MS, also called direct infusion MS (DIMS), where the 
sample gets directly injected into the MS machine without the necessity to perform any  
separation/purification steps prior to the injection. Both techniques have their specific 
advantages, disadvantages and similarities. In most mass spectrometers used nowadays for 
lipid analysis the ionization technique of choice is the electrospray ionization (ESI), which can 
be run in positive- and negative-ion modes. Both techniques provide detailed quantitative 
information about hundreds of lipid species per measurement, what has opened new 
possibilities and provided new insights into lipid biology. MS helped to pave the way to a better 
understanding of the vital role of different lipid species as membrane building blocks, as well 
as of their bioactive functions. The promise that lipidomics hold is that, due to the involvement 
of lipids in many crucial  (in particular metabolic) pathways, a better understanding as well as 
faster and cheaper analysis of the lipidome could and would lead to the discovery of potential 
new biomarkers to monitor human health and disease (Surma et al., 2015; Sales et al., 2016, 
p. 201). 
Both MS methods begin with the lipid extraction from the biological sample. LC-MS involves 
LC separation either based on the lipid class, e.g. normal-phase LC (NPLC), or lipid species, 
e.g. reversed-phase LC (RPLC). Once the partitioned lipid molecules are separated, they are 
injected into the MS, where they get directly evaporated and ionized in the ion source. 
Subsequently, the generated ions are sorted in an electric field with changing polarities.  
A widespread method currently used involves quadrupoles - sets of four parallel electrically 
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connected metal rods.  Therein, radio frequency voltage is applied with a slightly offset direct 
current in a way that the opposing metal rods have the same frequency. Hence, ions that are 
travelling alongside the quadrupoles are separated depending on their mass-to-charge ratio 
(m/z). Depending on the used MS, there can be one or several quadrupoles in series. 
Eventually the ion masses are being detected. which, again, can be performed in several 
possible ways. One option is to measure the time-of-flight (TOF). In this approach ions are 
accelerated in one constant electric field, resulting on all the ions having the same potential. 
Next, the time needed by the ions to reach the detector is measured. Lighter ions have less 
tendency for a curved trajectory and therefore reach the detector faster than heavier ions, given 
that all the ions have the same charge.  
Another commonly used mass detector comprises so called ion traps, where ions are captured 
and sequentially ejected. To do so, the ion trap mass analyzers use a combination of electric 
and magnetic fields to capture the ions. Again, several variants of ion traps exist, e.g. 3D and 
linear ion traps. The advantage of MS machines that possess an ion trap is that the ions can 
be stored and multiple gas-phase fragmentation (MS/MS) experiments can be performed on 
the same specimen. Fragmentation is an important tool to gather additional structural 
information by computationally assembling the acquired fragments into mass spectral trees. 
The reasons why the majority of laboratories prefer LC-MS over the direct infusion shotgun-
MS are the more reliable identification of individual lipid species, including the ones with low 
quantity levels, the possibility to separate between isomers and isobars, as well as the reduced 
ion suppression effects. With newer generations of LC instruments also the chromatographic 
separation became more efficient by reduction of analysis time and solvent consumption (Li et 
al., 2011). 
The most important strength of shotgun-MS simultaneously poses its biggest challenge - the 
injection of crude lipid extracts. It is the injection of the total lipid extract that makes this method 
so versatile and suitable for high throughput measurements, however, at the same time, it 
hampers the identification of the lipids of interest. Depending on the specific ionization and the 
resulting adduct formation properties, separation can be achieved in-source (Han et al., 2004; 
Schwudke et al., 2007). However, the development of the Orbitrap Thermo Fischer shotgun 
mass spectrometers has overcome the separation problem owing to their superior resolution. 
Using these machines shotgun lipidomics have emerged as the method of choice for high 
throughput analysis. With the shotgun approach a large amount of lipidomic data for various 
tissues (Han et al., 2006; Sewell et al., 2012) and organisms, such as yeast (Ejsing et al., 2009; 
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Klose and Tarasov, 2016) and Drosophila (Carvalho et al., 2012), has already been provided. 
Due to the direct injection of the total lipid extract and the lack of pre-separation, the low 
abundant lipid species can be missed as a result of their suppression by predominant lipid 
classes. Hence, ion suppression and ion enhancement effects are a major challenge for all 
electrospray based ionization methods (Yang and Han, 2011).  
1.7.5. Characteristics and disadvantages of Shotgun-MS versus LC-MS  
When comparing with LC-MS, the injection of crude/total lipid extracts into the shotgun-MS 
results in higher background during the acquisition, arguably resulting in lower sensitivity for 
the direct infusion. A separation of isomeric lipid species is not possible with shotgun-MS alone, 
while it is possible with LC-MS. If not provided with a solid know-how and a software like 
LipidXplorer (Herzog et al., 2012),an in-depth characterization of lipid species in crude lipid 
extracts may be more complicated than with LC-MS, where, for example, retention times can 
help with identification of acquired peaks. Both methods typically use tandem mass 
spectrometry (MS/MS) to analyze low abundant lipid mediator species. It can occur that one 
precursor ion produces different fragments, indicating that there are possibly several 
molecules, in which case a deconvolution may help to distinguish which fragments originated 
from which precursor molecule group. 
However, for shotgun mass spectrometry suppression is the same for all lipids and therefore 
can be corrected by suitable standards more conveniently than in LC-MS, where each injected 
fraction has a different matrix and thus different suppression. 
To be able to normalize the intensity output from MS data, it is necessary to use internal 
standards that are added to the sample before any extraction or separation procedure is 
performed. Consequently, the analytes and the internal standards are present in the same 
sample matrix and undergo the same ion suppression and matrix effects. Finding suitable 
internal standards (IS) can prove to be difficult, since the IS must mirror both the chemical and 
the physical behavior of its analyte as close as possible, while being a unique entity itself in 
terms of its sum composition and molecular weight. In the lipidomic field opinions still vary how 
many and under which aspects internal standards have to be used and reporting criteria have 
been put out for discussion (Liebisch et al., 2017). 
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1.8.  The goal of this thesis 
The goal of this project was to explore whether the direct infusion shotgun mass spectrometry 
can be employed for ganglioside analysis. Previously reported extractions and analytical 
methods have either been too complicated, time consuming, or required too much sample 
material and are therefore limited in their application. Hence, there is still the need for improved 
ganglioside analysis tools, which could contribute towards a better molecular understanding of 
their roles in neuronal microdomains and their impact on such essential processes as brain 
development, differentiation of neuronal cells, cell-cell interactions, signal transduction and 
synapse formation. Deciphering not only the ganglioside distribution but the overall membrane 
composition during these cellular events may provide answers to some of the most fundamental 
questions. The goal of this thesis is to add such a novel analytical method, that is capable to 
quantify individual ganglioside species and is sensitive enough to detect also the fine 
differences in the lipid composition of the membranes, while at the same time being able to put 
the findings in the bigger picture provided by the measurement of the remaining lipidome. 
The following imperative will be to integrate the new method as smoothly as possible into the 
preexisting high-throughput shotgun mass spectrometry workflow and, eventually, make it and 
inherent part of it (Surma et al., 2015). To reach this goal, certain criteria must be met, e.g. the 
reproducibility needs to be on the same level as the rest of the measured lipidomic data the 
same applying to the number of samples that can be processed simultaneously. But most 
importantly, the new method needs to be able to work with the water phase in which the 
gangliosides reside and which is left after the lipids that partition into the organic solvent phase 
have been extracted. This limitation can be overcome owing to the polar nature of the sugar 
moieties from the gangliosides, but with the downstroke of losing sensitivity. 
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2. Materials and Methods 
All the standard chemicals and reagents were purchased from Sigma Aldrich and Fisher 
Scientific. The lipid standards were purchased either from Avanti Lipids Inc. or Sigma Aldrich. 
 
Importantly, it must be acknowledged, that all plasticware used in this protocol cannot be made 
from polystyrene, due to the extraction of organic plasticizers and stabilizers such as phthalates 
and butylated hydroxytoluene (BHT) by the used organic solvent, namely chloroform. For this 
reason, all plasticware needs to be made from polypropylene (PP) or polyethylene (PE). 
Therefore, for all done extraction solely products from Eppendorf™ (PP) were used. 
Nevertheless, PP and PE only have a higher resistance to chloroform, hence it is recommended 
to minimize the exposure to chloroform as much as possible. 
A special acknowledgement goes to Ludger Johannes from the Institute Curie in Paris, France. 
The collaboration with him made it possible to get ganglioside class specific standards for most 
ganglioside classes of interest, namely GM1, GD1 and GT1.  
2.1.  Materials 
2.1.1. Chemicals and consumables 
Chemicals, materials and consumables were obtained from the companies and with the 
catalogue numbers, shown in Table 2, Table 3 and Table 4. 
Chemical Company Cat # 
Acetone (HiPerSolv) VWR GmbH, Darmstadt, Germany 20067-320 
Ammonium bicarbonate (ABC) Sigma Aldrich, St. Louis, USA 
11213-1KG-
R 
Di-isopropyl ether Sigma Aldrich, St. Louis, USA 38270-1L-F 
Chloroform CHROMASOL® for 
HPLC 
VWR GmbH, Darmstadt, Germany 83627-290 
Chloroform (HiPerSolv) VWR GmbH, Darmstadt, Germany 18G054007 
1-Butanol Sigma Aldrich, St. Louis, USA 33065-1L-R 
2-Propanol Fisher Scientific, Geel, Belgium A461-212 
Ethanol absolute VWR GmbH, Darmstadt, Germany 20621-310 
Methanol Optima® LC/MS Grade 
Fisher Scientific, Loughborough, 
UK 
1076-7665 
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Methylamine solution Sigma Aldrich, St. Louis, USA BCBK0866V 
Neuaminidase (Sialidase) Sigma Aldrich, St. Louis, USA 11585886001 
Non-fat dried milk Carnation Co., Los Angeles, USA NA 
Sodium chloride Sigma Aldrich, St. Louis, USA 091M0095V 
Table 2. Chemicals. 
 
Material Company Cat # 
Deep well plate 2 ml Corning™; Sigma Aldrich, St. 
Louis, USA 
3961 
2 ml amber glas vial Supelco / Merck KGaA, 
Darmstadt, Germany 
29653-U 
4 ml amber glas vial Supelco / Merck KGaA, 
Darmstadt, Germany 
27115-U 
Robot tips 300 µl Hamilton Robotics, Martinsried, 
Germany 
235902 
Robot tips 1000 µl Hamilton Robotics, Martinsried, 
Germany 
235904 
Sealing Alu-foil Corning™; Sigma Aldrich, St. 
Louis, USA 
734-1774 
SOLA™ SPE plates, HRP 10 
mg/2 ml 96-well 
Fisher Scientific, Loughborough, 
UK 
11899163 
Pierce™ C-18 Spin 
Columns 8 mg C-18 resin 
Thermo Fisher Scientific, 
Waltham, USA 
89873 
Ultrasonic bath Sonorex Bandelin GmbH & Co KG, Berlin, 
Germany 
303 
Vacuum Manifold 
VacMaster™ 96 
Biotage AB, Uppsala, Sweden 121-9600 
Table 3. Used materials list. 
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Ganglioside Class Manufacturer/Supplier Cat # 
Mixed porcine brain 
gangliosides 
Avanti Polar Lipids Inc.  860053P-10mg 
Ovine GM1 Standard Avanti Polar Lipids Inc. 860065P-1mg 
Bovine GM1 Standard Sigma Aldrich, St. Louis, USA G7641 
Bovine GD1a Standard Matreya LLC, State College, USA 1062 
Bovine GT1b Standard Matreya LLC, State College, USA 1063 
Bovine GT1b Standard Sigma Aldrich, St. Louis, USA G3767-1MG 
Bovine GQ1b Standard Matreya LLC, State College, USA 1064 
C17-GM1b Standard 
Ludger Johannes Lab (Curie-Institute, 
Paris, France) 
N/A (custom 
made) 
C17.2-GM1b Standard 
Ludger Johannes Lab (Curie-Institute, 
Paris, France) 
N/A (custom 
made) 
C17-GD1a Standard 
Ludger Johannes Lab (Curie-Institute, 
Paris, France) 
N/A (custom 
made) 
C17- GT1b Standard 
Ludger Johannes Lab (Curie-Institute, 
Paris, France) 
N/A (custom 
made) 
Table 4. Used Gangliosides Standards; the bovine ganglioside standards were purchased as shown and 
used for evaluating the method as well as determining the LOD and LOQ in titration versus the fitting 
class of C17 standard; the C17 standards were custom made by the Ludger Johannes Lab and therefore 
do not possess a Cat #. 
For the purification of gangliosides out of the total lipid extract (TLE) the Pierce™ C-18 Spin 
Columns from Thermo Scientific, Rockford, USA (Cat # 89870), were used. At a later stage of 
the project SOLA™ SPE-96 well plates, also from Thermo Fisher Scientific (Cat # 60309-001), 
were adapted. The advantage of these SOLA plates is the tight packing of the sorbent, 
preventing cavities and tunnels in it, and generally performing with a higher reproducibility. 
Additionally, there was no plate equivalent for the Pierce™ C-18 Spin Columns, limiting the 
number of samples that could be handled per run to 24, thus preventing a high-throughput 
approach and resulting, combined with the improved reproducibility, in the switch to SOLA™ 
plates after they became commercially available.  
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2.1.2. Reagent mixes 
Name Amount 
Methanol 50 ml 
Chloroform 10 ml 
Methylamine Solution 30 µl 
Table 5. Mass spectrometer injection mix methylamine. 
 
Name Amount 
Water 1 l 
Ammonium bicarbonate 11.85 g 
Table 6. Ammonium Bicarbonate (ABC) solution for cell or tissue dilution. 
2.2.  Methods 
2.2.1. Lipid extraction methods 
The final version of the lipid extraction and processing protocol is described in the following. 
The starting protocol, how it was evaluated and the evolution to the final protocol are described 
in detail in the result sections 3.1 and 3.3. 
In the first extraction step with the TLE, and after adding the internal standards, 750 µl of 
chloroform/methanol (C/M) 10:1 mixture was added to 150 µl of 150 mM ABC and shaken at 
1,400 rpm for 2 h at 4°C. Then, the mixture was centrifugated at 3,000 g for 5 min at 4°C. The 
upper (organic) phase was subsequently transferred to a new 2 ml Eppendorf™ tube and the 
second extraction step was performed by adding 750 µl of C/M 2:1 mixture shaking at  
1,400 rpm for 2 h at 4°C and centrifugation at 3,000 g for 5 min at 4°C. Contrary to the starting 
protocol (see chapter 3.1) it is not necessary anymore with the final protocol to evaporate the 
aquatic phase before loading it on the columns for the solid phase extraction, which allows to 
reduce time needed to perform the protocol from 1,5days to 10 h.  
Equilibration of the SOLA™ plates was done by adding 400 µl methanol, followed by 5 min 
incubation and draining the plate via the vacuum manifold. Next, the plates were treated in 
subsequent steps with 400 µl of C/M 2:1, followed by methanol and eventually methanol/water 
(M/W) 1:1, each liquid with a 5 min incubation time and draining by vacuum before applying the 
next liquid. For the sample loading a 96 deep well plate was positioned underneath the SOLA™ 
 
38 
 
plate, to catch the loaded samples while being able to load them in total 3 times with 2 min 
incubation steps in between. The introduction of the SOLA™ plates combined with the vacuum 
manifold reduced the hands-on worktime additionally, together with the direct loading of the 
aquatic phase onto the SPE columns. With the SOLA™ plates it was not necessary anymore 
to load the individual spin columns manually in and out of the centrifuge for each spinning and 
the required time to perform the 20 washing steps was therefore reduced considerably. For the 
washing in total 8 ml of H2O per column were added and drained with the vacuum system. 
Afterwards, a new 96 deep well plate was positioned underneath the SOLA™ plate to catch 
the eluate. Elution was done by pipetting first 400 µl methanol per column followed by 5 min 
incubation and subsequently drainage by vacuum and repeating these steps twice with 400 µl 
chloroform/methanol 1:1. Eventually, the eluate was transferred into 1.5 ml Eppendorf™ tubes 
and evaporated. Thanks to the improved packing of the SOLA™ compared to the loose Pierce 
C18 resin bed, further steps to get rid of the remaining column material were not necessary 
anymore. After evaporation, the purified extracts could be resuspended in smaller compared 
to previous protocol volume of 20 µl MS-mix MA, resulting in a higher sample concentration for 
the injection into the mass spectrometer. After addition of the 20 µl MS-mix MA, the extracts 
were shaken for 10 min at 1,400 rpm, 4°C and then transferred to a 96 well plate and injected 
into the mass spectrometer. 
2.2.2. Infusion and MS method 
The machines used for the acquisitions were Q-Exactive™ from Thermo Fisher Scientific 
coupled with the Triversa NanoMate™ from Advion Bioscience for automated microchip Nano 
electrospray infusion. A sample volume of 5 µl was injected into the MS with a gas pressure of 
0.8 psi (pound pressure per square inch). Applied voltage for ESI was 0.95 kV. Acquisition was 
done in the negative ion mode. Delivery times varied depending on the measured samples and 
experimental setting. The contact closure delay was set to 5 s to avoid initial spray instability.  
The measured mass-to-charge ratio (m/z) windows were chosen to fit the individual ganglioside 
classes (i.o. GM1, GD1, GT1, GQ1) being double negative charged and for the two most 
dominant species (36:1 and 38:1) with the modified C17-ganglioside standards (35:1) (see 
Table 4) still laying within these m/z windows (see Table 7).  
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Ganglioside 
Class 
Ionization 
m/z of 
Species 
35:1 
(d18:1/17:0) 
m/z of 
Species 
36:1 
(d18:1/18:0) 
m/z of 
Species 
38:1 
(d18:1/20:0) 
Used m/z 
window 
GM1 [M−2H]2− 764.92 771.93 785.95 760-795 
GD1 [M−2H]2− 910.475 917.48 931.49 905-940 
GT1 [M−2H]2− 1056.02 1063.03 1077.04 1050-1085 
GQ1 [M−2H]2− N/A 1208.57 1222.59 1200-1235 
Table 7. The m/z of individual ganglioside classes of interest, if they are double charged, and out of that 
resulting m/z windows for the measurements. For GQ1 no modified C17-ganglioside class standard is 
available and due to the generally low abundancy of GQ1 the mass window was held narrower. 
Acquisition times for each measured m/z segment also varied over the course of the project 
but were usually within 20 s – 30 s per acquired lipid class. All individual scans in every segment 
are the average of 2 microscans. Automatic gain control (AGC) was set to 1 x 106 and maximum 
ion injection time (IT) to 500 ms. For a long time, it occasionally happened that in a few 
individual scans a little shoulder appeared at the peak of interest, that was closer towards the 
in the Molecular Fragmentation Query Language (MFQL) defined m/z and hence preferred in 
the final output file generated by LipidXplorer over the main peak. This artifact required 
laborious manual analysis of the raw files, which, unavoidably, was less reproducible than 
automated analysis. Solution to this problem was the combination of the common background 
molecules with the lock mass function (Schuhmann et al., 2012). Measured m/z windows had 
a width of 35 Dalton (Da), but for quality control also acquisitions with narrower windows of  
5 Da around each individual species of interest were performed. 
2.2.3. Analysis of Shotgun-MS lipidomic data 
All data were analyzed with an in-house developed lipid identification software called 
LipidXplorer (Herzog et al., 2011, 2012). Tolerance for MS identification was set to 4ppm 
without lock mass and 2 ppm with lock mass activated. Data post-processing and normalization 
were performed using an in-house developed data management system. Data visualization, 
linear regression (linear least squares method), and correlation (two-tailed Pearson correlation) 
calculations were performed either manually or with the statistical analysis software “R”. 
Mass spectrometry-based lipid analysis was performed by Lipotype GmbH (Dresden, 
Germany) as described elsewhere (Sampaio et al., 2011). Lipids were extracted using a two-
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step chloroform/methanol procedure (Ejsing et al., 2009). Samples were spiked with internal 
lipid standard mixture containing: cardiolipin 16:1/15:0/15:0/15:0 (CL), ceramide 18:1;2/17:0 
(Cer), diacylglycerol 17:0/17:0 (DAG), hexosylceramide 18:1;2/12:0 (HexCer), lyso-
phosphatidate 17:0 (LPA), lyso-phosphatidylcholine 12:0 (LPC), lyso-
phosphatidylethanolamine 17:1 (LPE), lyso-phosphatidylglycerol 17:1 (LPG), lyso-
phosphatidylinositol 17:1 (LPI), lyso-phosphatidylserine 17:1 (LPS), phosphatidate 17:0/17:0 
(PA), phosphatidylcholine 17:0/17:0 (PC), phosphatidylethanolamine 17:0/17:0 (PE), 
phosphatidylglycerol 17:0/17:0 (PG), phosphatidylinositol 16:0/16:0 (PI), phosphatidylserine 
17:0/17:0 (PS), cholesterol ester 20:0 (CE), sphingomyelin 18:1;2/12:0;0 (SM), triacylglycerol 
17:0/17:0/17:0 (TAG) and cholesterol D6 (Chol). After extraction, the organic phase was 
transferred to an infusion plate and dried in a speed vacuum concentrator. Dry extract was 
resuspended in 33% ethanol solution of methylamine in chloroform/methanol (0.003:5:1; 
V:V:V). All liquid handling steps were performed using Hamilton Robotics STARlet robotic 
platform with the Anti Droplet Control feature for organic solvents pipetting. 
2.2.4. MS data acquisition 
Samples were analyzed by direct infusion into the QExactive mass spectrometer (Thermo 
Scientific) equipped with a TriVersa NanoMate ion source (Advion Biosciences). Samples were 
analyzed in both positive and negative ion modes with a resolution of Rm/z=200=280000 for MS 
and Rm/z=200=17500 for MSMS experiments, in a single acquisition. MSMS was triggered by an 
inclusion list encompassing corresponding MS mass ranges scanned in 1 Da increments 
(Surma et al., 2015). Both MS and MSMS data were combined to monitor CE, DAG and TAG 
ions as ammonium adducts; PC, PC O-, as acetate adducts; and CL, PA, PE, PE O-, PG, PI 
and PS as deprotonated anions. MS only was used to monitor LPA, LPE, LPE O-, LPI and LPS 
as deprotonated anions; Cer, HexCer, SM, LPC and LPC O- as acetate adducts and cholesterol 
as ammonium adduct of an acetylated derivative (Liebisch et al., 2006). 
2.2.5. Data analysis and post-processing 
Data were analyzed with an in-house developed lipid identification software based on 
LipidXplorer (Herzog et al., 2011, 2012). Data post-processing and normalization were 
performed using an in-house developed data management system. Only lipid identifications 
with a signal-to-noise ratio >5, and a signal intensity 5-fold higher than in corresponding blank 
samples were considered for further data analysis (Surma et al., 2015). 
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Also, for evaluation and optimization of the initial protocol a statistical software called Optival™ 
from the company Quodata GmbH was used. This software helped to identify the critical 
working steps of the protocol and to determine the optimal conditions, e.g. salt concentrations, 
for these steps of the protocol (see chapter 3.2). 
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3. Results 
The goal of this thesis was to develop a direct infusion shotgun mass spectrometry protocol for 
the four major mammalian brain gangliosides, that would operate within the same parameters, 
e.g. coefficient of variance (CV), as the previously established protocols for the Lipotype GmbH 
(Surma et al., 2015). Additionally, the developed protocol should also be more sensitive than 
the so far existing protocols for brain gangliosides, while requiring less sample material (Fong 
et al., 2009; Ikeda et al., 2008). One of the biggest challenges throughout this project was to 
obtain suitable internal standards that share close physico-chemical behavior with the analyte, 
while being unique, meaning they do not, or only in insignificant amount, occur naturally in the 
sample material. Commonly deuterated standards are used for that purpose in lipidomics, but 
there are no deuterated ganglioside standards commercially available. This presented a major 
obstacle for the project. In an attempt to circumvent it, a deuterated standard for 
phosphatidylethanolamine (PE) (Surma et al., 2015) was tested, but to no avail, as its physico-
chemical behavior was not compatible to gangliosides.  
The first parts of the results chapter are dedicated to the starting protocol and to explain how 
and why it has evolved over time (see chapters 3.1-3.3). Subsequent attempts to establish an 
alternative internal standard for quantification as long as no modified C17-ganglioside 
standards were available, are described in chapter 3.4. Later, the fitting ganglioside class 
specific standards were obtained and subsequently incorporated to the protocol, as described 
in chapters 3.5-3.7. The unique feature of these standards, also referred to as the modified 
ganglioside standards, is the lack of the fatty acid moiety which has been enzymatically 
removed and replaced by a 17-carbon atom long aliphatic chain, resulting in a GM1 35:1 
species. Gangliosides carrying such odd-numbered fatty acids do not occur naturally, or are 
found in very low amounts, among the brain ganglioside species, thus have a great potential 
to serve as suitable internal standards. At first it was only possible to obtain a modified standard 
for ganglioside GM1b, C17-GM1b. While the results with the C17-GM1b standard proved far 
superior to any results achieved with the PE standard, further experiments with the PE standard 
were stopped (see chapter 3.4). A response factor for the other three ganglioside classes, 
namely GD1, GT1 and GQ1, was empirically established with the modified C17-GM1b standard 
(see chapter 3.5). Later, also modified C17-ganglioside standards for the ganglioside classes 
GD1a and GT1b could be procured. For ganglioside class GQ1b it was not possible to get a 
specific internal standard, but modified C17-GT1b proved to be the most fitting standard and 
was subsequently used for the quantification of GQ1b with its corresponding response factor 
(see chapter 3.5). Simultaneously, the limits of detection (LOD) as well as the limits of 
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quantification (LOQ) were determined for each of the major mammalian brain ganglioside 
classes were determined by titrating different concentrations of ganglioside standards versus 
a steady concentration of the fitting modified C17-ganglioside standard (see chapter 3.6). 
Eventually, the evaluated starting protocol was tested by using it to quantify different wet weight 
amounts of a mix of mouse brains. The measured amounts of gangliosides reflected the values 
described in literature (see chapter 1.5). Ultimately, chapter 3.9 presents the final test of the 
protocol in an applied experimental setting, that aimed at quantifying the lipid content - 
gangliosides as well as other lipids - in two different mouse brain regions - cerebellum and 
hemisphere - at mice of different age (4 days, 14 days, 21 days, 8 weeks and 18 months after 
birth).  
3.1.  The starting protocol 
As a starting point for the ganglioside extraction, a slightly modified version of the extraction 
protocol of Ladisch et al. (Ladisch and Gillard, 1985) and Svennerholm & Fredman 
(Svennerholm and Fredman, 1980) was used with a mixture of chloroform/methanol/water 
(C/M/W) 4:8:3. The protocol we used, employed 150 mM of  ammonium bicarbonate (ABC) 
solution instead of water. The first step, after thawing the samples, was always to add 50 pmol 
of the internal standards. Commonly all handled tissue/cell samples were frozen in 300 µl of 
150 mM ABC and hence 800 µl methanol and 400 µl chloroform were added to reach C/M/W 
4:8:3. Then, the extraction was done by shaking for 30 min at room temperature, followed by 
centrifugation for 10 min at 16,000 x g at 4°C. The supernatant was transferred to a fresh 2 ml 
Eppendorf™ tube and evaporated. The total lipid extract (TLE) was subsequently dissolved in 
100 µl of C/M 1:1 and sonicated for 10 min, centrifuged again (10 min, 16,000 x g, 4°C) to 
remove insoluble material, transferred to a new 2 ml Eppendorf™ tube and evaporated.  
To separate between the bulk of non-polar lipids and the polar lipids, to which gangliosides 
belong, the total lipid extraction needed to undergo a 2-phase partitioning process. For that, 
the total lipid extract (TLE) was dispersed in 400 µl of di-isopropyl ether/1-butanol 6:4, vortexed 
and sonicated for 10 min. Afterwards, 200 µl of 10 mM aqueous NaCl solution were added, 
vortexed and shaken for 10 min at 180 g (equals 1,400 rpm) and 4°C, and centrifuged for 5 min 
at 4,000 x g and 4°C. In the end of the procedure gangliosides were present in the lower, 
aqueous 10 mM NaCl phase. The organic (upper) phase was removed and disposed, while the 
aqueous phase was extracted another time with 400 µl of di-isopropyl ether/1-butanol 6:4 by 
vortexing and shaking for 10 min at 1,400 rpm and 4°C, subsequent centrifugation for 5 min at 
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4,000 x g and 4°C, to speed up the phase separation, and disposal of the organic phase. 
Eventually, the supernatant was evaporated overnight.  
The next stage of the extraction was the solid phase extraction (SPE) which was done during 
the starting protocol stage with Pierce™ C18 resin spin columns (see chapter 2.1.1). All the 
steps of the SPE were performed at room temperature. First, the extract needed to be dissolved 
in 100 µl methanol, sonicated for 10 min, then 100 µl of MS-grade pure H2O was added, 
followed by another 10 min of sonication. In parallel, the equilibration of the SPE columns was 
done. To do so, the SPE columns were put on top of 2 ml Eppendorf™ tubes and 400 µl of 
methanol were dispensed at the side wall of each column, with attention to not disturb the resin 
bed. The columns were left standing for 5 min and then centrifugation for 1 min at 16,000 x g. 
Subsequently, the above steps were repeated with 400 µl of C/M 2:1, methanol, and eventually 
M/W 1:1. Afterwards, the sample could be loaded on the column and let stand for 2 min before 
a centrifugation for 1 min at 1,500 x g was done. The sample was then loaded again two more 
times on the columns. After the samples were loaded, the columns were washed 20 times with 
400 µl H2O and centrifuged for 30 s at 1,500 x g. Next, the C18 spin columns were transferred 
to fresh 2 ml Eppendorf™ tubes. Subsequently, the glycosphingolipids were eluted first with 
400 µl methanol and next, two times with 400 µl C/M 1:1, followed by incubation for 5 min and 
centrifugation for 30 s at 15,000 x g. Eluates were pooled in 1.5 ml Eppendorf™ tubes and the 
supernatant was evaporated. Eventually, the samples were resuspended in 50 µl methylamine 
MS-mix (see chapter 2.1.2) and shaken for 10 min at 180 x g and 4°C. To get rid of column 
material that could still be present in the Eppendorf tube, a final centrifugation step at  
16,000 x g for 10 min at 4°C was performed and 30 µl of supernatant was transferred to  
a 96 well plate and analyzed by shotgun lipidomics. Injections were done with an Advion 
TriVersa Nanomate system. All the experiments were measured with the Thermo Scientific Q 
Exactive mass spectrometer. 
The individual steps of this starting protocol were evaluated under the aspects of an evaluation 
software called Optival™ from the company Quodata.  
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3.2.  Protocol evaluation 
One of the first major phases of this project was the identification and evaluation of the 
protocol’s working steps, that could significantly impact the outcome of each experiment and 
to assess the optimal conditions (see Table 8). 
Salt conc. in 2-phase 
partitioning 
No. of sample loadings 
on resin columns 
No. of washing steps 
0 mM 1 3 
10 mM 3 10 
50 mM 5 20 
Table 8. Working steps of the protocol that could significantly impact the result needed to be evaluated 
for the most optimal outcome in regard to sensitivity and reproducibility. Additionally, to the three different 
salt concentrations in the water phase of the 2-phase partitioning, number of sample loading on SPE 
columns and the number of washing steps were also tested if the MS-mix volume of 30 µl or 50 µl has a 
significant impact. 
 
The evaluation was done with the help of the OptiVal™ software (Quodata). This software 
applies statistical methods to provide the user with a detailed analysis of performed 
experiments, in order to maximize the sensitivity and intensity of the outcome, as well as 
minimize random and systemic errors. The experiment was designed to test each factor of the 
four variables in triplicates, resulting in a total of 162 samples. At this time, each sample had to 
be handled manually, with single spin columns for the lipid extract purification, meaning a 
maximum of 24 samples per run could be handled simultaneously. Also the initial protocol took 
2 days for the performance of a single run. Thus, the OptiVal™ experiment was carried out 
over the course of 7 days, where on the second day of each run the first day of the next run 
had to be started. To provide a lipid background that is free of gangliosides, HEL-SCR cells of 
the human erythroleukemia cell line were used as starting material, containing 3600 pmol total 
lipid per sample. To that an ovine GM1 brain extract standard (Avanti Inc., see Table 4) was 
added in the amount of 100 pmol per sample. 
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Figure 5. Dispersion plot of protocol evaluation with the number of sample loadings as portrayed 
influence factor. X-axis shows the tested parameters, in this case the varying salt concentrations for the 
aqueous. phase during the 2-phase partitioning and the number of washing steps per SPE column during 
the total lipid extract purification. Y-Axis: With the signal-to-noise (S/N) ratio of the used GM1 standards 
in the evaluation experiment, the OptiVal™ software calculated a response factor (Y-axis values) for 
each evaluation point to quantify the corresponding uncertainty associated with each influence factor. 
The higher the score the better the setting is in terms of reproducibility and sensitivity. 
 
The outcome of the experiment is shown in Figure 5 and Figure 6. Each of the individual 
evaluation points (see X-axis) in the dispersion plot shown in Figure 5 illustrates either  
a different salt concentration in the aqueous phase during the 2-phase partitioning or a different 
amount of washing steps of the resin columns. Based on the measured signal to noise (S/N) 
ratios, the OptiVal™ software calculated for each point a response value. The higher the 
response value the better it is in regard to its impact on the sensitivity. With the replicates the 
reproducibility for each point was calculated and is pictured here as a spread shape. The first 
three, middle three and the last three points have the same salt concentration but differ in the 
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number of performed washing steps (see Figure 5). The tested numbers of sample loadings 
are represented with different colors: green, red and blue for respectively 1, 3 and 5 sample 
loadings. Salt concentration of 10 mM for the 2-phase partitioning shows the biggest spread, 
but also the highest calculated response, reflecting the achieved sensitivity. The condition with 
10 mM salt and 20 washing steps had its lowest response equal to or higher than the other 
conditions, but it outperformed them at the top response value, while showing not much 
variation about the number of sample loadings.  
For a more detailed illustration, Figure 6 shows a multivariant analysis of the 10 mM salt 
concentration condition only. The highest signal intensity, which directly translated to the 
protocol sensitivity, was obtained with triple sample loading and 20 washing steps. Hence, 
these conditions along with 10 mM salt concentration for the aquatic phase in the 2-phase 
partitioning were identified as the most optimal and adapted in future ganglioside extraction 
experiments. 
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Figure 6. Multivariant analysis showing the impact of a 10 mM salt concentration during the 2-phase 
partitioning step in context with a varying number of sample loadings and washing steps. Intermediate 
values, that were not included in the experiment itself, e.g. “number of sample loading 2.4” were 
automatically calculated by the software. It is clear to see, that the conditions with the most optimal output 
are 3 sample loadings, 20 washing steps and with a salt concentration of 10 mM for the aquatic phase 
in the 2-phase partitioning.  
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3.3.  Final protocol 
The following section presents the final version of the extraction and analysis protocol for the 
major brain gangliosides of mammals. The starting protocol and its improvement over time are 
described in the previous result sections. While spin column ganglioside extraction offered 
good results in terms of sensitivity, the reproducibility could still be improved. Additionally,  
a major bottleneck of spin column approach was the maximum handling capacity of only  
24 samples per run, which made it impossible to measure bigger sample sets together and 
required splitting the samples into several separate MS measurements. This posed a serious 
problem, since MS machines always show a slight signal drift or instability over time, and the 
more time passes between two measurements the stronger it becomes, adding an 
unnecessary variation to the final outcome. The signal drift may occur due to sample 
adsorption, degradation, or insulating deposits on the hot stainless steel surface of the ion 
source (D’Autry et al., 2010), but also different humidity and air pressure may contribute to it. It 
is possible to address the signal shifting problem with the help of reference samples, but it is 
still preferable to measure all samples subsequently in one experiment. This was the reason 
for switching from spin columns to SOLA™ plates once they became commercially available. 
Apart from enabling to process more samples at a time, the SOLA™ plates had other 
advantages. For example, the resin packaging methods were improved, leading to less tunnels 
and cavities in the resin bed of the SOLA™ plates compared to the loose bed of spin column 
resin. This alone increased the  reproducibility of ganglioside extraction (“Thermo Scientific 
SOLA SPE cartridges and plates Technical Guide,” n.d.).  
The introduction of SOLA™ plates was also accompanied with some other changes in the 
extraction protocol, required to better fit into the workflow of other protocols, e.g. the general 
lipidomic analysis. Hence, as a first extraction step with the TLE and after adding the internal 
standards, 750 µl chloroform/methanol 10:1 were added to 150 µl of 150 mM ABC, shaken for 
2 h at 1,400 rpm and 4°C and centrifuged at 3,000 x g for 5 min at 4°C. The upper (organic) 
phase was subsequently transferred to a new 2 ml Eppendorf™ tube and the second extraction 
step was performed by adding 750 µl of chloroform/methanol 2:1, again followed by shaking 
for 2 h at 1,400 rpm, 4°C and centrifugation at 3,000 x g for 5 min at 4°C. Here, it was not 
necessary anymore to evaporate the aquatic phase and resuspend it in 200 µl of M/W 1:1, 
before loading the samples on the columns for the solid phase extraction, helping to reduce the 
time needed for the protocol 1.5 days to 10 h.  
The rest of the final protocol was already described in chapter 2.2.1 Lipid extraction methods 
and can be found there. 
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3.4. Alternative internal standards 
To be able to quantify the measured gangliosides in samples, before the modified C17-
ganglioside standards were obtained, experiments were performed with a deuterated PE 
standard. Since the deuterated PE standard would not bind to the resin columns it could not be 
applied at the beginning of the extraction and undergo the exact same process as the 
endogenous gangliosides. Therefore, standard could only be added to the final mixture that is 
injected into the mass spectrometer and hence could not account for the material loss that 
naturally occurs during the extraction process. This would result in the measured ganglioside 
concentration being lower than their actual concentration in the sample. Furthermore, due to 
the direct addition of the deuterated PE standard to the MS-injection mixture it was difficult to 
spike the right amount. Usually ending up with a to high concentrated standard in the injected 
mixture and therefor overloading the ion trap during the acquisition, even further miss 
representing what is measured from the original sample concentration (see Figure 7). Overall, 
it was not feasible to continue without a better fitting standard. 
 
Figure 7. Alternative internal standard test. y-Axis shows the measured Signal to Noise (S/N) ratio. Pre 
S/N = GM1- and deuterated PE standard were added equimolar and directly injected into MS; Post S/N 
= GM1 standard was processed with evaluated protocol, deuterated PE standard added “equimolar” to 
the beginning concentration of GM1 standard before injection into MS. Since the deuterated PE standard 
cannot bind to the SPE columns and therefore can only be added post extraction to the MS-mix before 
injection in the MS. Thus, the deuterated PE standard cannot account for all the losses that may occur 
during the extraction and suppressing the ions of interest in the ion-trap by being overrepresented. 
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3.5. Response Factors of modified GM1 standard for naturally occurring GD1, 
GT1 and GQ1 
Due to the lack of fitting internal standards for each ganglioside class of interest it was 
necessary to empirically determine response factors (RF) for the classes. A response factor 
addresses the differences in the way molecules ionize and other physico-chemical differences 
during sample handling, e.g. one ganglioside class could be more polar than another and hence 
more prone to go to the aquatic phase or bind more specifically to the C18 resin columns during 
the 2-phase extraction. Thus, over several experiments the RF for each ganglioside class were 
determined empirically and calculated with the following formula: 
𝑅𝐹 =
𝐼𝑛𝑡𝑤𝑡(36:1)
𝐼𝑛𝑡𝑀𝑜𝑑.𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 
Subsequently the RF values were averaged. With these RFs the mouse brain titration with only 
modified C17-GM1b as an internal standard was done (See Table 9). Nevertheless, a response 
factor will always be only an approximation and can never replace a suitable standard from the 
same lipid class.  
 
Ganglioside Class Response Factors (RFs) Variation of RFs 
GD1 2.682 1.48 - 4.74 
GT1 0.258 0.085 - 0.412 
GQ1 0.0048 0.0028 - 0.074 
Table 9. Empirically determined response factors (RFs) of modified C17-GM1 standard for the other 
ganglioside classes. 
3.6. Limit of detection (LOD) and limit of quantification (LOQ) for each 
ganglioside class 
As mentioned before, for the determination of the limit of detection (LOD) as well as the limit of 
quantification (LOQ) a titration of bovine ganglioside standards was done, measured and 
compared to a constant concentration of the modified C17-GM1 standard. A known and stable 
concentration of the modified C17 standard was added to ganglioside-free human 
erythroleukemia cell line HEL-SCR, to provide a lipid background, and the ganglioside class to 
be assessed (for used ganglioside standards see Table 4). The physico-chemical behavior of 
endogenous GM1 should mirror the behavior of the used standard and therefore a comparison 
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of the measured intensities is a valid way to describe the concentration proportions in the 
sample. For gangliosides other than GM1, a response factor was empirically allocated by 
measuring samples containing the same concentration of, for example, the GD1 standard and 
the C17-GM1 standard. The measured intensity deviation for the same standard concentration 
made it possible to calculate the response factor. This was repeated for different concentrations 
and on several days using two mass spectrometers, to get robust data for the response factors 
(see Table 9).  
After assessment of the response factors for modified C17-GM1b towards the other ganglioside 
classes, the LOD and LOQ could be calculated via a linear regression based on a linear 
calibration curve (see Figures 8-13). The calculation was done by titrating a constant 
concentration of 50 pmol of C17-GM1b standard versus a range of non-modified ganglioside 
standards concentrations ranging from 1600 pmol to 0.73 pmol in 1:3 dilution steps. For the 
linear regression to work it is assumed that the instrument response y is linearly related to the 
standard concentration x for a limited range of concentration: 
𝑦 = 𝑎 + 𝑥𝑏 
This model can then be used to calculate the sensitivity b together with the LOD and LOQ: 
𝐿𝑂𝐷 = 3
𝑆𝐷
𝑚
 
𝐿𝑂𝑄 = 10
𝑆𝐷
𝑚
 
where SD stands for the standard deviation and m for the slope of the calibration curve. 
LOD describes the ability to measure the existence of a signal reliably and LOQ is the minimal 
concentration that must be present in a sample in order to be able to measure the concentration 
reliably. The results stated in Table 10 are the LOD and LOQ for the evaluated starting protocol. 
 
Class (Evaluated Protocol) LOD (pmol) LOQ (pmol) 
GM1 3.86 15.73 
GD1 8.97 12.25 
GT1 15.94 44.16 
GQ1 34.63 47.37 
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Table 10. Limit of detection (LOD) and limit of quantification (LOQ) in pmol values for each ganglioside 
class of interest obtained with the evaluated (=old) protocol. Notably, for these values only the modified 
C17-GM1 standard was available for the measurements, which is also reflected in the higher LODs and 
LOQs for the other classes. 
At a later stage of the project also modified C17-ganglioside standards for the classes GD1a 
and GT1b had been kindly provided by Ludger Johannes (Curie-Institute, Paris, France) and 
could be used for measuring these classes with them. By not having to use the approximating 
RFs for these classes anymore the LOD and LOQ could be improved compared to before, 
where the modified C17-GM1 had to be used for all ganglioside classes of interest. Additionally, 
GT1b as a molecule is more like GQ1b, compared to GM1b, and assessing the LOD as well 
as LOQ of GQ1b via the modified C17-GT1b standard helped to improve these values. 
In Table 11 a significant improvement of LOD and LOQ for each ganglioside class can be seen, 
which can be attributed to two reasons: firstly, the use of fitting class standards for GD1 and 
GT1 as well as the use of modified C17-GT1b as the new reference standard for GQ1b; 
secondly, changes on the protocol to increase its performance and integrate it better into the 
workflow for non-ganglioside lipidomic acquisition. As stated before, these changes included 
the switch to SOLA™ plates accompanied with usage of a vacuum manifold and streamlining 
of the extraction process as described in the final protocol (see Section 3.3).  
Class (Final Protocol) LOD (pmol) LOQ (pmol) 
GM1 (36:1) 0.393 1.19 
GM1 (38:1) 0.644 1.95 
GD1 (36:1) 0.243 0.74 
GD1 (38:1) 0.3 0.911 
GT1 (36:1) 0.658 1.99 
GT1 (38:1) 0.796 2.413 
GQ1 (36:1) 1.683 5.10 
GQ1 (38:1) 4.1 12.432 
Table 11. Limit of detection (LOD) and limit of quantification (LOQ) values obtained with the final protocol, 
using the three modified C17-ganglioside standards for the classes GM1b, GD1a, GT1b and SOLA™ 
plates. Even though the LOD and LOQ for GQ1 improved significantly when it was assessed via modified 
C17-GT1b compared to the assessment via modified C17-GM1b, with a modified GQ1 standard the 
values would most likely be further reduced and resemble more the values of the other ganglioside 
classes. 
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A mass range window of 30 Da was used during each acquisition. Within this 30 Da window all 
the mass over charge (M/Z) peaks of interest are located: Namely, the 36:1 and 38:1 peaks 
(the two most abundant naturally occurring ganglioside species (see 1.3), when double 
negatively charged), as well as the 35:1 peak of the modified C17-standards. In Figure 8 the 
titration curve for non-modified (=wildtype) GM1b versus a constant concentration of the 
modified C17-GM1b standard is shown. The calculated LOD lies at 3.86 pmol and the LOQ at 
15.73 pmol. On the y-axis the responsive behavior of the constant internal standard to the 
changing GM1b standard is indicated. To provide a ganglioside-free lipid background per 
sample circa 80,000 human erythrocyte leukemic cells were used, that should equal a total lipid 
amount of 4000 pmol. All the following assessment experiments were performed in a similar 
fashion.  
 
Figure 8. GM1b standard titration with HEL cells and the evaluated (=older) protocol, to provide lipid 
background, normalized to modified GM1; Acquired Mass Range: 30 Da. 
 
Figure 9 shows the results for GD1 under the same conditions of acquisition as previously 
stated for the GM1 class, the used internal standard was still the modified C17-GM1b standard. 
The calculated LOD lies at 8.97 pmol and the LOQ at 12.25 pmol for GD1, when normalized to 
C17-GM1b.  
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Figure 9. GD1a standard titration with HEL cells and the evaluated (=older) protocol, to provide lipid 
background, normalized to modified C17-GM1; Acquired Mass Range: 30 Da; LOD: 8.97 pmol; LOQ: 
12.25 pmol. 
For the GT1b standard titration, done with the evaluated starting protocol under the same 
conditions as previously stated and normalized to C17-GM1b, the LOD was 15.94 pmol and 
the LOQ 44.16 pmol (see Figure 10). 
  
Figure 10. GT1b standard titration with HEL cells and the evaluated (=older) protocol, to provide lipid 
background, normalized to modified GM1; Acquired Mass Range: 30 Da; LOD: 15.94 pmol; LOQ: 
44.16 pmol. 
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For GQ1b standard titration, same settings and evaluated protocol, the LOD was 34.63 pmol 
and LOQ 47.37 pmol (see Figure 11). Noticeably, LOD and LOQ diminish with increasing 
complexity of the measured ganglioside and the subsequent gap between measured 
ganglioside class and the C17-GM1b standard. Due to the lack of availability of a more fitting 
GQ1b standard, this was the best approximation possible at that time. To give a comparison, 
publications regarding the quantification of gangliosides by mass spectrometry alone are 
scarce, quantification was either done with calculation by the ratios of individual peak areas of 
ganglioside molecular species to the total peak area (Ikeda et al., 2008) or by calculation of 
signal to noise (S/N) ratios (Fong et al., 2009). There, the LOD was estimated by loading 
decreasing amounts of ganglioside standard on to the HPLC–MS system until the peak was 
three times the noise level, while the LOQ was estimated to be as three times the LOD. These 
data were obtained with LC-MS, and, to the best of our knowledge, there has been no 
publication quantifying gangliosides via Shotgun mass spectrometry so far. 
 
Figure 11. GQ1b standard titration with HEL cells and the evaluated (=older) protocol, to provide lipid 
background, normalized to modified GM1; Acquired Mass Range: 30 Dalton; LOD: 34.63 pmol; LOQ: 
47.37 pmol. 
The results presented in Figures 8-11 were obtained with the evaluated (=older) protocol and 
normalized towards the C17-GM1b standard. Upon arrival of the modified GD1a and GT1b the 
LOD and LOQ needed to be reassessed. Hence, the previous experiments were repeated with 
a standard titration from 1.5 pmol to 1000 pmol with the set of non-modified bovine standards 
(see Table 4), while the modified C17-standards remained at 100 pmol. The new standard 
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titration was also done with the improved final protocol and the LOD as well as the LOQ have 
already been stated in Table 11. The standard titration curve for species 36:1 can be seen in 
Figure 12 and for species 38:1 in Figure 13.  
 
Figure 12. The standard titration curves for all ganglioside species 36:1 to determine the LOD & LOQ via 
all three modified C17 standards (GM1b, GD1a, GT1b) and final protocol. Wildtype ganglioside standard 
titration versus a steady concentration of matching modified C17-ganglioside standards with the final 
protocol, using SOLA™ plates and vacuum manifold. The individual graphs show intensity ratios of the 
standards (Wildtype vs. Modified) towards each other; GQ1 shows more outliers due to the lack of  
a class specific modified C17-standard. Modified C17-GT1b standard was used for the normalization of 
class GQ1.  
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Figure 13. The standard titration curves for ganglioside species 38:1. to determine the LOD & LOQ via 
all three modified C17 standards (GM1b, GD1a, GT1b) and final protocol. Wildtype ganglioside standard 
titration versus a steady concentration of matching modified C17-ganglioside standards with the final 
protocol, using SOLA™ plates and vacuum manifold. The individual graphs show intensity ratios of the 
standards (Wildtype vs. Modified) towards each other; GQ1 shows more outliers due to the lack of  
a class specific modified C17-standard. Modified C17-GT1b standard was used for the normalization of 
class GQ1. 
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For both species the results for GQ1b are not as good as for the other ganglioside classes, this 
problem could most likely be addressed with a fitting class standard. After normalizing GQ1b 
to the three modified C17-standards individually, modified C17-GT1b showed the results 
closest to the expected outcome and was used from then on for normalization of GQ1b.  
 
3.7. Technical variation 
To assess the reproducibility of a method, the technical variation between biological replicates, 
the coefficient of variance (CV) are determined. The CV is calculated with the following formula: 
𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
∗ 100 
 
Six samples with an equimolar concentration of 100 pmol of non-modified bovine ganglioside 
standards as well as the modified C17-standards were measured subsequently. The results for 
the evaluated protocol with all three modified standards are shown in Table 12.  
 
Ganglioside CV-average 
GM1a 8.13 
GD1a/b 11.86 
GT1b 7.7 
GQ1b 30.79 
Table 12. Average Coefficient of Variance (CV) for the different Ganglioside classes with evaluated 
(=older) protocol and all three modified C17-ganglioside standards. 
For the same experimental set-up with the final protocol the CV values can be found in Table 
13. 
Ganglioside CV-average 
GM1a 5.64 
GD1a/b 2.81 
GT1b 5.13 
GQ1b 18.43 
Table 13. Average Coefficient of Variance (CV) for the different Ganglioside classes with the final 
protocol and all three modified C17-ganglioside standards. 
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3.8. Testing under biological conditions: brain tissue titrations 
As a proof of principal experiment and to determine the performance under biological conditions 
a titration of various amounts of mouse brain tissue was done. In this experiment the two most 
abundant ganglioside species with regard to their ceramide headgroup, 36:1 and 38:1 of the 
four major ganglioside classes in mammal brains were of interest, as explained in 1.3 Structure 
and biosynthesis of glycolipids. The experimental setting for the results shown in Figure 14, 
was to process triplicates of 150 µg, 300 µg and 600 µg of wet weight mouse brain tissue 
together with 100 pmol of modified C17-GM1 standard with the evaluated protocol. In the used 
mouse brain 100 µg of wet weight tissue should equal a total lipid concentration of about 
4600 pmol. This experiment was done at an earlier stage of the project, after the arrival and 
establishment of only the modified C17-GM1b standard, which was also before the other 
changes were applied to the protocol (e.g. SOLA™ plates and vacuum manifold). Therefore, 
comparing these results with the data obtained after repeating the experiment with the final 
protocol and all three modified C17-ganglioside standards later, allows to illustrate the overall 
enhancement of the method’s performance. 
After the acquisition the intensity values were extracted from the raw files with the help of 
LipotypeXplorer, subsequently normalized with regard to the modified GM1b standard and 
quantified with the response factors listed in Table 9. 
The results were within expected parameters (see Figure 14). The only exception were the 
results obtained for GT1b: first, the measured concentration of 36:1 and 38:1 GT1b at 300 µg 
of tissue was lower than the concentration at 150 µg of the same tissue. Secondly, also the 
measured increase from 150 µg to 600 µg was lower than expected. By increasing the amount 
of tissue 4-fold one would expect a proportional increase in the measured ganglioside 
concentration. The measured values were, however, much lower and not even a 2-fold increase 
was observed between 150 µg and 600 µg input samples. This observation cannot be 
explained only by matrix effects. Possible reasons for this are a non-homogenous sample 
material distribution during pipetting or ion suppression in the ion trap due to too high GD1 
amount. 
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Figure 14. Brain tissue titration with evaluated (=old) protocol and all shown gangliosides species 
normalized to modified C17-GM1b. Y-Axis shows measured concentration in pmol. X-Axis shows mean 
values (triplicates) for the two dominant lipid species (36:1 and 38:1) for the four major mammal brain 
ganglioside classes. Error bars are +/- of Standard deviation (SD). Titration of wet weight mouse brain 
tissue was done with 600 µg (blue), 300 µg (orange) and 150 µg (grey) and in triplicates. The 2-fold 
increase of wet weight mouse brain tissue over the titration should also be reflected in a similar increase 
of measured ganglioside concentration. The stagnation for the 600 µg wet weight samples could be 
explained with matrix effects and a possible ion suppression in the ion trap by GD1. For GT1 36:1 and 
38:1 with 300 µg of wet weight brain tissue the concentration was lower than for the 150 µg wet weight 
samples. A possible reason could be a non-homogenous distribution of sample material while pipetting, 
but this would have lowered the measured concentrations for the other ganglioside classes equally and 
not only for GT1. 
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At a later stage of the project, after also the modified ganglioside standards arrived for GD1a 
and GT1b, the above experiment was repeated, with a slightly broader titration range of the 
used mouse brain tissue amount: from 100 µg to 1000 µg wet weight (Figure 15), where again 
100 µg of wet weight tissue would equal around 4600 pmol of total lipid. The final protocol was 
used to obtain these data, employing 100 pmol from each of the three modified ganglioside 
standards and SOLA™ plates in combination with the vacuum manifold. The measured 
quantities are in accordance to the findings of other studies (Ikeda et al., 2008; Fong et al., 
2009). The error bars are clearly much smaller than in the previous experiment, which could 
not only be attributed to the fitting class standards, but also a result of the different acquisitional 
mass windows used in this experiment. If there is no fitting class standard with a mass over 
charge (m/z) ratio that lays close to the m/z ratio of the peaks of interest, it is necessary to 
either make a very broad acquisitional window that includes both, the standard as well as the 
peaks of interest, or make two individual windows. A broader acquisitional m/z window means 
a higher noise level. But the low abundance of GQ1b required as few background as possible, 
therefor two separate m/z acquisition windows were set, resulting in the standard peaks and 
the peaks of interest being measured separately from each other. The m/z of the double 
negatively charged modified C17-GM1b standard is at 764,92 and for 38:1 of GQ1b at 
1.222,59, meaning the acquisitional window would need to span more than 457 Da (see Table 
7) to measure the peaks of interest in one acquisition. Measuring in separate acquisitions 
commonly increases the spread in mass spectrometry. 
The measured concentrations for GQ1b were also improved and reflected what was expected 
from the literature (Ikeda et al., 2008). 
 
 
 
Figure 15. Brain tissue titration with evaluated (=old) protocol and all shown gangliosides species normalized to their respective modified C17-Standard, 
except for GQ1 which was normalized to modified C17-GT1b standard. Y-Axis shows measured concentration in pmol. X-Axis shows the mean values 
(triplicates) for the two dominant lipid species (36:1 and 38:1) for the four major mammal brain ganglioside classes. Error bars are +/- of Standard 
deviation (SD). Titration of wet weight whole mouse brain tissue was done with 1,000 µg, 800 µg, 600 µg, 400 µg, 200 µg and 150 µg wet weight in 
triplicates. Results improved considerably compared to the previous brain tissue titration with only modified C17-GM1 as internal standard. 
GM1 36:1 GM1 38:1 GD1 36:1 GD1 38:1 GT1 36:1 GT1 38:1 GQ1 36:1 GQ1 38:1
1000 µg wet weight 190,46 31,41 700,78 191,56 181,86 76,51 4,52 2,44
800 µg wet weight 161,06 24,30 509,49 136,05 138,76 54,98 3,61 1,85
600 µg wet weight 83,26 11,48 319,97 81,80 77,56 30,74 2,14 1,56
400 µg wet weight 63,25 9,53 255,09 62,27 59,92 23,62 1,06 0,74
200 µg wet weight 37,74 5,52 122,57 31,14 33,39 13,37 0,87 0,64
100 µg wet weight 16,41 2,61 72,70 15,24 15,40 6,25 0,79 0,25
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3.9. Biological application: ganglioside measurement in murine cerebellum and 
hemispheres at different developmental stages 
In a biological application the final version of the protocol was applied to two different brain areas, 
the cerebellum (cereb) and brain hemispheres (hemis), in mouse brains at five different 
developmental stages: postnatal day 4 (P4), day 14 (P14) and day 21 (P21), 8 weeks (8w) and 
18 month (18m) after birth. The complexity of mammal brain gangliosides should be increasing 
over time (Fong et al., 2009) and the goal was to find out if we can measure this change in the 
different developmental stages and if we can observe a significant difference in between the two 
brain areas, not only for gangliosides, but for all lipid classes globally. Hence, we conducted first 
an exploratory experiment to get an idea of the total lipid amount per sample, where only 
phosphatidylcholine (PC) is measured for the same amount of tissue (wet weight). This is done to 
have comparable amounts of total lipid for the following experiment. Subsequently, the lipid 
composition at previously stated developmental time points and in the two brain areas is assessed. 
A general trend in the lipid class composition cannot be observed. Most abundant lipid class  
4 days after birth (P4) is phosphatidylcholine (PC) and its percentage of total lipid goes down over 
time, while this trend can be observed in a reversed manner for cholesterol. Similarly, the 
percentage of total lipids is shifting between phosphatidylethanolamine (PE) and (PE O-) with a 
lower abundance in the early days after birth, which is steadily increasing throughout first weeks 
after birth, thus making up an increasing fraction of the total lipids. For the other lipid classes, no 
clear trend can be observed (see Figure 16). The ganglioside classes are shown in more detail in 
Figure 17 and in Figures 19-21. At most of the time points measured from the hemisphere, 
gangliosides of the 36:1 species make up a bigger part of the total lipid than in the cerebellum. 
This trend seems to be reversed in the 38:1 ganglioside species, where the gangliosides make up 
a bigger part in the total lipids than in the hemisphere.  
Contrary to our expectations, the amount of measured gangliosides reduces after birth over time, 
the same can be said for ceramide (Cer) and sphingomyelin (SM) in the cerebellum, but not for 
the hemispheres. The only sphingolipid class opposing this trend is hexosylceramide (HexCer) 
(Figure 16-17).
 
 
 
 
Figure 16. Lipid class composition of all lipids in mol% of total lipids Overall most abundant lipid class 4 days after birth (P4) is phosphatidylcholine (PC) 
and its percentage of total lipid goes down over time, while this trend can be observed in a reversed manner for cholesterol. Similarly, the percentage 
of total lipids is shifting between phosphatidylethanolamine (PE) and (PE O). For the other lipid classes, no clear trend can be observed. P4 = postnatal 
day 4; P14 = postnatal day 14; P21 = postnatal day 21; 8w = postnatal week 8; 18 months = postnatal month 18; C = Cerebellum; H = Hemisphere. 
Triplicates were measured for each sample, mean is shown, error bars are +/- SD. For a more detailed view regarding the sphingolipid classes see 
Figure 17.
 
 
 
Figure 17. Lipid composition of sphingolipids classes in mol%; P4 = postnatal day 4; P14 = postnatal day 14; P21 = postnatal day 21; 8w = postnatal 
week 8; 18 months = postnatal month 18; C = Cerebellum; H = Hemisphere. Triplicates were measured for each sample, the values shown represent 
mean +/- SD. Remark: Only sphingolipids are observed in this graph, not the whole lipidome, therefor the given proportions apply to sphingolipids and 
not the whole lipidome. After birth the amount of gangliosides reduces over time, the same can be said for ceramide (Cer) and sphingomyelin (SM) in 
the cerebellum, but not for the hemispheres. The only sphingolipid class opposing this trend is HexCer. 
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Subsequently, a principal component analysis (PCA) was performed, which showed that the first 
principal component (PC) is the tissue of origin and the second PC is the developmental stage 
(see Figure 18), as to be expected. Generally, in PCAs, an orthogonal transformation is done to 
convert a set of observations of possibly correlated variables into a set of values of linearly 
uncorrelated variables, also called principal components. Usually, the PCA operation can be 
thought of as revealing the internal structure of the data in a way that best explains the variance 
in the data. If a dataset with several variants is visualized as a set of coordinates in a high-
dimensional data space (1 axis per variable), PCA can supply the user with a lower-dimensional 
picture - a projection of this object when viewed from its most informative viewpoint. This is done 
by using only the first few principal components, so that the dimensionality of the transformed data 
is reduced.  
 
 
Figure 18. Principal component analysis (PCA) with tissue (PC1) and age (PC2) as principal components. 
Lipid class composition of all lipids in mol% of total lipids; P4 = postnatal day 4; P14 = postnatal day 14; 
P21 = postnatal day 21; 8w = postnatal week 8; 18 months = postnatal month 18; C = Cerebellum; H = 
Hemisphere. PCA is used as a statistical tool to prove if correlation between samples is given and as a test 
of plausibility the biological replicates need to cluster in the PCA. These data include the global lipid analysis 
combined with the ganglioside analysis. All samples were measured in Triplicates. 
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The chain length has significant impact on the properties of the fatty acid and the lipid itself. 
Generally, the longer an alkyl chain is, the higher the melting point of it. On the other hand, the 
shorter a fatty acid is less saturated the better is its fluidity, which is a common feature that animal 
cells require to maintain the fluidity of their cell membranes during varying temperatures. In Figure 
19 the carbon chain length of the aliphatic head groups is shown.  
The carbon chain length of fatty acids can also be of importance when it comes to extracellular 
export via micelles that can act as emulsifiers, e.g. to transport fat-soluble vitamins or other lipids. 
The same is true for the amount of double bonds (DB) within an alkyl chain. It may be saturated, 
meaning with no double bonds, or unsaturated, usually with one or two double bonds. Mostly 
occurring DBs in unsaturated fatty acids are in cis-formation and in polyunsaturated fatty acids 
generally separated by at least one methylene group. Unsaturated fatty acids have lower melting 
points than saturated fatty acids of the same length. Double bonds cause bending of the 
hydrocarbon chain, which is why the fatty acids cannot compact tightly together and the van der 
Waals interaction between the fatty acids are reduced. Hence, the number of DBs per ganglioside 
class may help to contribute to our understanding of the biological function of gangliosides in the 
central nervous system. The number of DBs at different developmental stages in the mouse brain 
was measured (see Figure 20). 
 
 
 
 
Figure 19. Carbon chain length of ganglioside classes shown in mol% per class; P4 = postnatal day 4; P14 = postnatal day 14; P21 = postnatal day 21; 
8w = postnatal week 8; 18 month = postnatal month 18; C = Cerebellum; H = Hemisphere; Triplicates were measured for each sample, shown is mean 
+/- SD. Aliphatic chains in biological system usually contain mostly an even number of carbon atoms and are unbranched; For brain gangliosides there 
is usually one or two dominant chain lengths. As expected, the dominant ganglioside species that could be observed are 36:1 and 38:1 and to a lesser 
extent 40:1. The chain length and degree of saturation usually characterizes its properties of the fatty acid and lipids. 
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Figure 20. Number of double bonds (DB) per ganglioside lipid class; P4 = postnatal day 4; P14 = postnatal 
day 14; P21 = postnatal day 21; 8w = postnatal week 8; 18 months = postnatal month 18; C = Cerebellum; 
H = Hemisphere. Triplicates were measured for each sample, shown is mean +/- SD. The quantity of single 
DBs seams to increase over time for GM1 and GQ1, while the amount of two DBs stagnates (GM1) or is 
reducing (GQ1) with progressing age of the mice. For GT1 this trend seems to be reversed, the single DBs 
get less over time and the number of two DBs goes up with age. For GD1 a different trend in the two different 
tissue types can be observed, in the cerebellum the number of single DBs diminishes while the number of 
two DBs grows. In tissue coming from the hemisphere it is the opposite for GD1.  
To provide even deeper characterization of the ganglioside classes across different 
developmental time-points of the mouse brain and to fully assess the possibilities of the final 
method of this protocol, in the next step also the hydroxyl groups of distinct ganglioside classes 
were quantified (Figure 21). The ganglioside class possess predominantly 2 hydroxyl groups (see 
Figure 21). While in GM1 and GQ1 no general trend is recognizable, the degree of hydroxylation 
in GT1 shifting from two hydroxyl groups to three. This can also be seen in the cerebellum in GD1. 
The amount of hydroxyl groups is important for the hydrophilic behavior of a molecule or the lack 
of such groups for its lipophilicity.  
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Figure 21. Degree of hydroxylation per ganglioside class shown in mol% per class; P4 = postnatal day 4; 
P14 = postnatal day 14; P21 = postnatal day 21; 8w = postnatal week 8; 18 months = postnatal month 18; 
C = Cerebellum; H = Hemisphere. Triplicates were measured for each sample, values represent mean +/- 
SD. Two hydroxyl groups prevail over all time points and in both tissues. In GT1 a general trend is 
recognizable with a shift from two hydroxyl groups to three. This can also be seen in the cerebellum in GD1. 
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4. Conclusion 
Lipids have long been neglected. One barrier to overcome was the lack of analytical methodology 
that could come to grips with the broad spectrum of lipid molecules to be analyzed. This was 
solved by the introduction of mass spectrometry. Today there are two platforms that are mostly 
being used, namely LC-MS and direct infusion (shotgun). The field is still dominated by LC-MS 
but shotgun-MS is gaining ground. The reason for this development is that the latter method is 
faster and at the same time more quantitative than LC-MS. 
One class of lipids that so far has not been included in the repertoire for shotgun-MS lipid analysis 
has been the gangliosides. They are exceptional in the sense that they are water-soluble, hence 
ending up in the water phase, after organic solvent extraction. They represent a poorly studied 
class of lipids because of the difficulty to analyze them with a resolution that extends the molecular 
level. Gangliosides are ubiquitous in their distribution over different tissues but show a higher 
concentration in the central nervous tissue and the liver (some refs). 
Thus, the aim of this thesis was to add an analytical tool with a higher sensitivity and more 
complete acquisition than currently existing comparable methods can offer for ganglioside 
analysis. Additionally, the method should have a sample procession time and reproducibility, that 
is on level with previously reported studies for shotgun mass spectrometric analysis of lipids 
(Surma et al., 2015). 
We wanted to achieve “complete acquisition” by measuring the gangliosides from the same 
sample as non-ganglioside lipids (Surma et al., 2015), thus opening new observation windows by 
increasing coverage. This was achieved by taking up the samples in 150 mM ammonium bi-
carbonate and subsequently extracting with chloroform/methanol 10:1 followed by 
chloroform/methanol 2:1 (see 3.3 Final protocol) and after the organic solvent extractions were 
done and used for non-ganglioside lipids analysis, the remaining ammonium bi-carbonate phase 
was used for the ganglioside extraction. 
This pursuit was successful. The method that we developed can be characterized as follows. The 
initial barrier that had to be overcome was to first standardize and subsequently automatize the 
extraction procedure as much as possible. Originally, the method started at the bi-phasic 
extraction protocol described by Svennerholm and Fredman (Svennerholm and Fredman, 1980), 
using chloroform/methanol/water 4:8:3. We ended up with a protocol, which included adjusting the 
salt concentration of the water phase during the extraction, increasing the number of sample 
loading on the C-18 resin columns as well as fixing the number of washing steps with H2O of the 
columns. These experiments were done with bovine ganglioside standards (see Table 4) and with 
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the human erythroleukemia cells, HEL-SCR, that have such a low ganglioside abundance, that 
they can be considered ganglioside-free.  
After the sensitivity yield was improved, the next phase of the project was to establish working 
internal standards to be able to quantify correctly the ganglioside concentration in complex 
biological samples. Deuterated ganglioside standards were not commercially available; hence the 
first experiments were carried out with internal standards used for the lipid class PE. Due to the 
different physio-chemical nature of this phospholipid compared to gangliosides, it could not be 
added at the beginning of the protocol. Additionally, PE did not bind to the C-18 resin columns, 
which is a necessary purification step of the protocol to separate the sialic acid carrying 
glycosphingolipids from the other polar lipids by means of their non-polar lipid head group. 
Therefore, the PE standard could not be used and had to be abandoned. 
Class-specific internal standards for the three major brain ganglioside classes, GM1, GD1 and 
GT1 could be obtained from the Ludger Johannes lab at the Curie-Institute in Paris, France. Here 
we gained access to ganglioside standards with a C17-fatty acid in the ceramide head group of 
these gangliosides, which occurs naturally in such low abundance that it can be used as an internal 
standard. These standards are commercially not available. Since these standards could be added 
to the sample to be analyzed before extraction, it was possible to achieve quantification as was 
demonstrated earlier for the global analysis protocol (Surma et al. 2015). 
Another important milestone for this thesis was the automatization of the protocol where it was 
feasible. Therefore, we switched from single C-18 resin spin columns to 96-well plates. This 
improved the processing speed of individual samples considerably. With the C-18 resin spin 
columns, it took approximately 16 hours to perform the whole protocol in one go and was 
additionally limited to 24 samples per processed batch. After the switch to 96-well plates, and the 
introduction of changes summed up in section 3.3 Final protocol, the processing time was reduced 
to 8.5 hours and the number of samples that can be processed simultaneously increased to 96. 
The acquisition at the MS data takes another 4 minutes per sample, resulting in an acquisition 
time of 6.4 hours for a whole 96-well plate. 
To determine the amounts of gangliosides required in a sample, the limit of quantification (LOQ) 
needed to be assessed. With the limit of detection (LOD) the sensitivity of this developed method 
was assessed (see 3.6. Limit of detection (LOD) and limit of quantification (LOQ) for each 
ganglioside class) as well as and coefficient of variance (CV) (3.7. Technical variation). The LOD 
and LOQ were defined with dynamic range experiments, were a stable concentration of each 
modified C17-ganglioside class standard was titrated against a variety of concentrations from the 
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corresponding regular ganglioside standards of its respective matching class. For the final protocol 
with all three modified standards the LOD is 0.0081 µM (for GD1 36:1) to 0.137 µM (for GQ1 38:1) 
and the LOQ is 0.025 µM (for GD1 36:1) to 12.432 µM (for GQ1 38:1). 
To be able to judge the effectiveness and parameters, e.g. sample amount, analysis time, LOD, 
LOQ, CV of a method, a comparison to other methods used to analyze gangliosides needs to be 
done. Fong et al. (2009) and Ikeda et al. (2008) are the benchmark studies for this purpose. In 
both publications LC-MS was used, which also reflects the predominant choice in the field, since 
LC-MS provides pre-separation of the lipids by chromatography and thus reduces the complexity 
of the mass spectrometric analysis. Typically, LC-MS has a higher sensitivity than Shotgun-MS, 
making it more suitable for analysis of low abundant classes of lipids – particularly with the use of 
LC-tandem mass spectrometry (LC-MS/MS) (Astarita et al., 2015). On the other hand, Shotgun-
MS offers the advantages of simplicity, saves time (no column separation), and the quantification 
is more straightforward, since the internal standards are in the same sample matrix and measured 
together with the analytes. The internal standards experience the same ion suppression and 
matrix effects and this feature makes the shotgun platform better suited for quantitative, high-
throughput and comprehensive lipid analysis than LC/MS/MS. The shotgun mass spectrometric 
method developed here clearly seems to be superior to the LC/MS/MS methods that we are using 
(for comparison see Table 14). 
 
Ikeda et al. 2008 Fong et al. 2009 This Thesis 
Method LC/ESI – MS/MS LC/ESI – MS/MS Shotgun MS/MS 
Used sample amount 500 mg mouse brain 
(25 weeks old) in 
16.6 ml 
 
Left-brain hemisphere 
of 2 d (0.4 – 0.45 g) & 
80 d (0.9 – 1 g) old 
rats in 5.05 ml 
Used 1/6 of extract (70 
– 170 µg) 
Variable (Tissue or cell 
culture) 
Minimum: 100 µg wet 
weight of brain tissue 
Chromatographic retention 
time 
Ca. 90 minutes Ca. 25 minutes 0 minutes 
Extraction - Individual (C/M/W – 
1:2:0.8) 
- Redisolve (C/M/W – 
30:60:8) 
- Washing (C/M/W – 
30:60:8) 
- Mod. Svennerholm 
and Fredman (C/M/W 
– 4:8:3) 
- Double Extraction 
- 2 Phase partitioning 
with 0.01 M KCl 
- - 150 mM ABC with 5x 
volume of C/M 10:1 
- - 150 mM ABC with 5x 
volume of C/M 2:1 
- - SOLA™ column 
purification 
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- Eluation (C/M/0.8M 
sodium acetate – 
30:60:8 
- Injection 
- Injection - - Evaporation 
- - Taken up in 20 µl 
methylamine mix (see 
Table 5) 
- - Injection 
Mass Spectrometer 4000Q TRAP 
Quadrupole-linear 
Ion Trap hybrid MS 
LTQ-Orbitrap™ Mass 
Spectrometer 
Q Exactive™ Hybrid 
Quadrupole-Orbitrap 
Mass Spectrometer 
Sensitivity Not stated Estimated via S/N ratio 
LOD = 0.146 – 
1.78 µM 
LOQ = 0.459 – 
5.31 µM  
Final: 
LOD = 0.0081 – 
0.137 µM 
LOQ = 0.025 – 
0.41 µM 
Technical variation: 
(Coefficiant of Variance = 
CV) 
Not stated CV: 4.8-12.3% CV: 5.1 % (w/o GQ1b) 
0.24% - 12.4 % (with 
GQ1b) 
(see Table 11 for 
details) 
Table 14. Method comparison. Retention time: while Shotgun-MS has no retention time, the column 
purification is an additional step that LC-MS methods do not have. Hence, the time required for column 
purification in this method replaces the retention time of the LC-MS methods. Sensitivity: LOD/LOQ range 
is calculated for required minimal amount of the major mammal brain gangliosides for two dominant species 
(namely, 36:1 and 38:1), lowest and highest values are stated for all ganglioside classes combined (for more 
details see Table 11). In regard to the CV values of GQ1b it has to be pointed out, that no class specific 
internal standard was available for this class throughout the project and it had to be quantified via the 
modified C17-GT1b class standard. Therefore, the CV of GQ1b is higher. 
Overall, the set goals for this method have been reached. It was possible to incorporate it into an 
pre-existing workflow (Surma et al., 2015) and have a higher sensitivity as well as shorter 
processing time than comparable method (see Table 14). Nevertheless, still a lot can be done to 
further enhance this protocol. 
To broaden the coverage of this method, further modified C17-ganglioside standards for other 
classes are required. Here, of particular importance would be the gangliosides associated with 
malignant development, e.g. GD2 (see section 1.6). Enhancing the repertoire of ganglioside 
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standards and application of our method could offer a valuable contribution to cancer research 
and diagnostics and help us unravel the roles gangliosides play in cancer.  
Finally, our method was on mouse brain tissue samples. The experiment, done with two different 
kinds of brain tissues (cerebellum and hemispheres) at different postnatal developmental stages, 
worked as a proof-of-concept in regard to the ability to perform a “complete acquisition”, by 
measuring for the first time the gangliosides and the non-ganglioside lipids simultaneously from 
the same sample. A complete acquisition platform now needs to be developed to establish a 
reliable combination of these two independently acquired data sets for studies of lipid biology and 
disease. Since no studies of this type have been done until now, it is not possible to compare our 
data with others. Importantly, is that ganglioside molecular species have not been quantitively 
measured in the brain or its individual regions so far. 
Overall, the method that we have developed will enable the ganglioside field to move into the 
molecular species era of lipid research. Little is known yet about their function, especially their role 
in the nervous system where they are concentrated. This new avenue is exciting and holds great 
promises for the future of the field. 
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5. Summary 
The goal of this thesis was to develop a high-throughput shotgun-MS lipidomics method to 
qualitatively and quantitively analyze the major mammalian brain ganglioside classes: GM1, GD1, 
GT1 and GQ1. As a starting point for the method to be developed, a modified ganglioside 
extraction method from Svennerholm and Ladisch was used (Svennerholm and Fredman, 1980; 
Ladisch and Gillard, 1985). The efficiencies and the impact of different extraction procedures to 
the overall performance were evaluated with a software called OptiVal™. The evaluation showed 
that the most important steps of the protocol are the salt concentration of the water phase during 
the 2-phase extraction, and 10 mM NaCl yielded the best sensitivity. Also, the number of washing 
steps with water during reverse solid phase extraction using C18 resin has a significant effect. 
The next step was to find suitable standards for quantification of the individual ganglioside classes. 
Since deuterated and alike ganglioside standards were commercially not available, we initially 
used a deuterated PE standard with limited success. 
A collaboration with the Ludger Johannes lab provided us with modified C17-ganglioside 
standards. The term “modified” describes the enzymatic exchange of the fatty acid in the 
hydrophobic tail by a 17-carbon atom long fatty acid. Since odd numbered fatty acids occur very 
rarely in nature, it is possible to use the measured intensity of the modified ceramide headgroup 
of 35:1 (Sphingosine C18:1 + Fatty Acid C17:0) to quantify natural gangliosides. Ideally, we would 
need to have a fitting modified C17-ganglioside standard for each class to be quantified. Since 
first only GM1 as a modified standard was available, it was necessary to determine response 
factors (RFs) for the ganglioside classes GD1, GT1 and GQ1. RFs were assessed empirically by 
titrating a variety of equimolar concentrations of the modified C17-GM1 standard versus wildtype 
standards of the other ganglioside classes. After establishment of the RFs it was possible to 
determine the limits of detection (LOD) and quantification (LOQ) for the ganglioside classes GD1, 
GT1 and GQ1 - with regard to the modified C17-GM1 standard. 
When the modified C17-standards for GD1 and GT1 became available, I was able to find out 
whether the correct internal standards are superior to the proxy method via response factors. The 
results clearly showed that the use of a correct class standards is preferable. For GQ1 no modified 
C17-standard was obtainable, therefore this class still has to be quantified via RFs. Experiments 
showed that the modified C17-GT1 standard is best suited for that. 
Another major goal was to integrate the ganglioside method into the general lipid analysis workflow 
of the high-throughput shotgun mass spectrometry platform that we were using. To achieve these 
goals adjustments on the evaluated (=old) protocol had to be done. These adjustments included 
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changes in the extraction steps from the Svennerholm & Ladisch more into the direction of a Bligh 
& Dyer based extraction method. This meant abandoning the 2-phase extraction step as well as 
the chloroform/methanol/water (C/M/W) 4:8:3 extraction, in favor of a C/M 10:1 followed by  
a C/M 2:1 extraction of 150 mM ammonium-bicarbonate water solution. The goal behind this was 
to enable a combination of the global lipidome extraction (Surma et al., 2015) with the ganglioside 
extraction.  
Another important improvement was scaling up the extraction process. The use of standard single 
solid phase extraction (SPE) cartridges was limiting the extraction throughput to only 24 samples 
at a time, therefore the single SPE cartridges were replaced with the 96-well SPE SOLA™ plates. 
To process the SOLA™ plates it was necessary to establish the usage of a vacuum manifold. 
Combined, these changes lowered the overall process time of the protocol from nearly two working 
days to one working day, without significant loss of sensitivity regarding the measured sample 
concentrations. This was assessed by performing the mouse brain tissue titration experiment, with 
all three modified C17-ganglioside class standards GM1, GD1 and GT1.  
Finally, the established method was applied to investigate the difference in ganglioside levels in 
the cerebellum compared to the brain hemispheres in mice of different age. First the C/M 10:1 and 
2:1 extraction was done for the analysis of all non-ganglioside lipids in the sample. The leftover 
water phase was then loaded onto the SOLA™ plates and processed with the new protocol. The 
results matched the given goals - to establish a protocol to measure and quantify the four major 
brain ganglioside classes in combination with the global lipidomics in a high-throughput manner - 
and thus were a success. 
To the best of our knowledge, this was the first time such a broad lipidomic measurement has 
been performed, hence no other studies exist to which the outcome could be compared.  
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6. Zusammenfassung 
Das Ziel dieser Dissertation war es eine Hochdurchsatz-Shotgun-MS Methode zur qualitativen 
und quantitativen Analyse der vier wichtigsten Gehirngangliosid-Klassen, namens GM1, GD1, 
GT1 und GQ1, von Säugetieren zu entwickeln. Als Ausgangspunkt für die Protokollentwicklung 
dienten die modifizierten Extraktionsmethoden von Svennerholm und Ladisch (Svennerholm and 
Fredman, 1980; Ladisch and Gillard, 1985). Um die Effizienz sowie die Auswirkungen einzelner 
Extraktionsschritte auf die Sensitivität dieser Methode auszutesten wurde sie zunächst mit Hilfe 
der Software OptiVal™ evaluiert. Diese Evaluierung zeigte, dass den größten Einfluss auf die 
Sensitivität während der Extraktion die Salzkonzentration der wässrigen Phase während der 2-
phasen Extraktion hat. Eine Salzkonzentration von 10mM NaCl zeigte die besten Resultate. 
Außerdem wurde offensichtlich, dass die Anzahl der Waschschritte mit Wasser während der 
umgekehrten Festphasenextraktion mit C18 Resin auch eine signifikante Rolle spielen mit der 
generellen Regel, je mehr Waschschritte umso besser das Ergebnis.  
Der nächste Schritt war es passende Standards zur Quantifizierung der einzelnen Gangliosid-
Klassen zu bekommen. Hierbei stellte es sich als Problem heraus, dass deuterierte oder 
vergleichbare Standards für diese Ganglioside kommerziell nicht verfügbar sind. Daher 
versuchten wir anfänglich einen deuterierten PE-Standard ersatzweise zu verwenden, mit 
begrenztem Erfolg. 
Eine Kooperation mit dem Ludger Johannes Labor ermöglichte es uns modifizierte C17-
Gangliosid-Standards zu erhalten. Mit dem Begriff „modifiziert“ ist gemeint, dass bei diesen 
Standards die Fettsäure aus der hydrophoben Ceramide-Kopfgruppe enzymatisch ausgetauscht 
wurde mit einer 17 Kohlenstoff Atom langen Fettsäure. Da Fettsäuren mit einer ungeraden Anzahl 
an Kohlenstoffatomen auf natürliche Weise nur äußerst selten vorkommen, ist es möglich einen 
solchen Standard mit einer 35:1 Kopfgruppe (Sphingosine C18:1 + Fettsäure C17:0) zur 
Quantifizierung von Gangliosiden zu verwenden. Ideal wäre es für jede Gangliosid-Klasse einen 
eigenen modifizierten Standard zu haben, aber zu Beginn war es nur möglich einen modifizierten 
Standard für GM1 zu bekommen. Um diesen Standard auch für die Gangliosid-Klassen GD1, GT1 
und GQ1 nutzen zu können war es notwendig zunächst sogenannte „Response Factors“ (RFs) 
empirisch zu bestimmen, diese RFs sollen das unterschiedliche chemische und physikalische 
Verhalten, z.B. Ionisierungsfähigkeit der Moleküle, der unterschiedlichen Klassen wiederspiegeln. 
Hierzu wurden die Intensitätsmessungen von verschiedenen äquimolaren Konzentrationen des 
modifizierten Standards mit den nicht-modifizierten Standards der anderen Gangliosid-Klassen 
verglichen. Nach der Bestimmung der RFs war es möglich weitere Parameter wie den 
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Streuungskoeffizienten, sowie die quantifizierbaren und detektierbaren Grenzen für die anderen 
Gangliosid-Klassen in Bezug auf den modifizierten GM1 Standard zu bestimmen. 
Mit der Zeit war es möglich auch noch modifizierte Standards für die Gangliosid-Klassen GD1 und 
GT1 zu erhalten und die Proxy-Ergebnisse via RFs mit den Messergebnissen passender 
Klassenstandards zu vergleichen. Das Ergebnis zeigte eindeutig, dass ein passender 
Klassenstandard zu bevorzugen ist, wo möglich. Für GQ1 war es nicht möglich einen solchen 
Standard zu bekommen, deswegen musste diese Klasse weiterhin mit Hilfe der RFs quantifiziert 
werden. Jedoch zeigte sich, dass der modifizierte GT1 Standard hierfür am besten geeignet ist. 
Ein weiteres wichtiges Ziel dieser Dissertation war es diese Methode in einen routinemäßigen 
Arbeitsablauf zur allgemeinen Hochdurchsatz-Lipidanalyse zu integrieren. Um diese Ziele zu 
erreichen waren einige Änderungen am mit OptiVal™ evaluierten Protokoll notwendig. Diese 
Anpassungen beinhalteten die Änderung von einer auf Svennerholm und Ladisch basierenden 
Gangliosid-Extraktionsmethode mehr hin zu einer auf Bligh und Dyer zurückgehende 
Extraktionsmethode. Dies bedeutete die Abschaffung der 2-phasen Extraktion. Der 
Extraktionsschritt mit einem Mischungsverhältnisses von Chloroform/Methanol/Wasser (C/M/W) 
von 4:8:3 wurde ersetzt mit einer C/M 10:1 gefolgt von einer C/M 2:1 Extraktion von 150µl einer 
150mM Ammonium-Bicarbonat wässrigen Lösung. Der Grund hierfür war es die Kombination 
einer bereits etablierten globalen Lipidanalyse-Methode (Surma et al., 2015) mit der hier 
etablierten Gangliosid-Analyse zu ermöglichen. 
Da die Nutzung von einzelnen SPE-Säulen dem Hochdurchsatzansatz im Weg stand, mussten 
diese zugunsten von 96-well Platten ersetzt werden. SPE-SOLA™ Platten wurden ab sofort 
verwendet. Um die SOLA™ Platten besser prozessieren zu können war die Etablierung eines 
Vacuum Manifolds notwendig. Alles in allem brachten diese Veränderungen eine Verringerung 
der Arbeitszeit des Protokolls von rund 2 Arbeitstagen auf einen Arbeitstag und das ohne 
Einbußen der Sensitivität für die gemessenen Konzentrationen. Dies wurde auch nochmals 
überprüft durch die Wiederholung der Titration von Mäusegehirngewebe, dieses Mal mit allen 3 
modifizierten Gangliosid-Standarden GM1, GD1 und GT1. Die Resultate dieses Versuches 
übertrafen die vorgegebenen Ziele und waren daher erfolgreich. 
Schließlich wurde die entwickelte Methode verwendet um die unterschiedlichen Gangliosid-Level 
von Cerebellum und Gehirnhemisphären von Mäusen unterschiedlichen Alters zu verglichen. Das 
bedeutet eine C/M 10:1 gefolgt von einer 2:1 Extraktion, um damit die nicht-Gangliosid Lipide zu 
extrahieren und zu bestimmen. Die verbleibende wässrige Phase konnte direkt auf die SOLA™-
Platten geladen und prozessiert werden, wie in 3.3 beschrieben.  
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Die Resultate waren in Übereinstimmung mit den vorgegebenen Zielen – ein Protokoll zu 
entwickeln mit dem die vier wichtigsten Gangliosid-Klassen in Gehirnen von Säugetieren 
gemessen und quantifiziert werden können, in Kombination mit der globalen Lipidomik-Analyse 
und in einem Hochdurchsatzverfahren – erreicht worden. 
Nach meinem besten Wissen wurde bislang keine vergleichbar Lipidanalyse von 
Säugetiergehirnen durchgeführt, bei der so viele Lipidklassen inklusive der Ganglioside qualitativ 
und quantitativ gemessen werden konnten und zu der diese Ergebnisse verglichen werden 
könnten. 
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